Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder

  • Strom, Nora I.|||0000-0002-5261-8852
  • Gerring, Zachary F.|||0000-0002-2445-1266
  • Galimberti, Marco|||0000-0001-6052-156X
  • Yu, Dongmei|||0000-0001-7901-4365
  • Halvorsen, Matthew W.|||0000-0002-6707-2418
  • Abdellaoui, Abdel|||0000-0003-1088-6784
  • Rodriguez-Fontenla, Cristina|||0000-0002-9829-6393
  • Sealock, Julia M.|||0000-0002-9346-3498
  • Bigdeli, Tim
  • Coleman, Jonathan R. I.|||0000-0002-6759-0944
  • Mahjani, Behrang|||0000-0001-6087-9537
  • Thorp, Jackson G.|||0000-0002-9461-6417
  • Bey, Katharina|||0000-0001-6392-4997
  • Burton, Christie L.|||0000-0002-8955-6528
  • Luykx, Jurjen J.|||0000-0002-6439-2774
  • Zai, Gwyneth|||0000-0002-0894-6867
  • Alemany Sierra, Silvia|||0000-0002-7925-6767
  • Andre, Christine
  • Askland, Kathleen D.|||0000-0003-1467-8923
  • Bäckman, Julia
  • Banaj, Nerisa|||0000-0002-6317-8549
  • Barlassina, Cristina|||0000-0001-7407-2697
  • Nissen, Judith Becker|||0000-0003-4063-6866
  • Bienvenu, O. Joseph|||0000-0002-8466-102X
  • Black, Donald|||0000-0001-8038-1971
  • Bloch, Michael H.|||0000-0003-0352-4080
  • Børte, Sigrid|||0000-0001-9540-3256
  • Bosch, Rosa|||0000-0002-7596-183X
  • Breen, Michael
  • Brennan, Brian P.|||0000-0001-5468-6552
  • Brentani, Helena|||0000-0001-5192-4682
  • Buxbaum, Joseph D.|||0000-0001-8898-8313
  • Bybjerg-Grauholm, Jonas|||0000-0003-1705-4008
  • Byrne, Enda M.|||0000-0002-9491-7797
  • Cabana-Domínguez, Judit|||0000-0002-4732-7284
  • Camarena, Beatriz
  • Camarena, Adrian|||0000-0001-8512-0607
  • Cappi, Carolina|||0000-0001-6661-3756
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Cavallini, Maria Cristina|||0000-0001-5913-1468
  • Ciullo, Valentina|||0000-0002-4095-7806
  • Cook, Edwin H.|||0000-0002-5848-5114
  • Crosby, Jesse
  • Cullen, Bernadette A.|||0000-0003-1762-092X
  • De Schipper, Elles J.|||0000-0001-9494-451X
  • Delorme, Richard|||0000-0002-5614-3663
  • Djurovic, Srdjan|||0000-0002-8140-8061
  • Elias, Jason A.
  • Estivill, Xavier|||0000-0002-0723-2256
  • Falkenstein, Martha J.|||0000-0001-5074-3409
  • Fundin, Bengt T.|||0000-0002-6037-7331
  • Garner, Lauryn
  • Gironda, Christina
  • Goes, Fernando S.|||0000-0001-6262-8264
  • Grados, Marco A.|||0000-0002-0178-1764
  • Grove, Jakob|||0000-0003-2284-5744
  • Guo, Wei|||0000-0002-4322-3699
  • Haavik, Jan|||0000-0001-7865-2808
  • Hagen, Kristen|||0000-0002-4286-1277
  • Harrington, Kelly|||0000-0001-9668-183X
  • Havdahl, Alexandra|||0000-0002-9268-0423
  • Höffler, Kira D.|||0000-0002-0837-1469
  • Hounie, Ana G.|||0000-0002-5026-2880
  • Hucks, Donald|||0000-0002-2700-5798
  • Hultman, Christina|||0000-0002-0327-2410
  • Janecka, Magdalena|||0000-0001-7406-0776
  • Jenike, Eric
  • Karlsson, Elinor K.|||0000-0002-4343-3776
  • Kelley, Kara
  • Klawohn, Julia|||0000-0002-9436-6948
  • Krasnow, Janice E.|||0000-0003-0316-6279
  • Krebs, Kristi|||0000-0003-0494-2751
  • Lange, Christoph|||0000-0002-9691-4741
  • Lanzagorta, Nuria|||0000-0001-6769-6813
  • Levey, Daniel|||0000-0001-8431-9569
  • Lindblad-Toh, Kerstin|||0000-0001-8338-0253
  • Macciardi, Fabio|||0000-0003-0537-4266
  • Maher, Brion|||0000-0001-9809-0064
  • Mathes, Brittany
  • McArthur, Evonne|||0000-0003-4566-4321
  • McGregor, Nathaniel|||0000-0001-7195-4993
  • McLaughlin, Nicole C.|||0000-0002-4016-2747
  • Meier, Sandra|||0000-0002-3287-5894
  • Miguel, Euripedes C.|||0000-0002-9393-3103
  • Mulhern, Maureen|||0000-0001-8642-4741
  • Nestadt, Paul S.
  • Nurmi, Erika L.|||0000-0003-4893-8957
  • O'Connell, Kevin S.|||0000-0002-6865-8795
  • Osiecki, Lisa|||0000-0002-9408-8722
  • Ousdal, Olga Therese|||0000-0002-0728-3141
  • Palviainen, Teemu|||0000-0002-7847-8384
  • Pedersen, Nancy L.|||0000-0001-8057-3543
  • Piras, Fabrizio|||0000-0003-3566-5494
  • Piras, Federica|||0000-0002-9546-7038
  • Potluri, Sriramya|||0000-0003-3877-0038
  • Rabionet, Raquel|||0000-0001-5006-8140
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Rauch, Scott|||0000-0001-7699-6754
  • Reichenberg, Abraham|||0000-0003-2729-8575
  • Riddle, Mark A.|||0000-0001-8764-2134
  • Ripke, Stephan|||0000-0003-3622-835X
  • Rosário, Maria C.|||0000-0002-8577-3306
  • Sampaio, Aline S.|||0000-0001-5568-6167
  • Schiele, Miriam A.|||0000-0003-2613-6515
  • Skogholt, Anne Heidi|||0000-0001-7466-0405
  • Sloofman, Laura G Sloofman G.|||0000-0001-7628-4378
  • Smit, Jan
  • Soler Artigas, María|||0000-0002-3213-1107
  • Thomas, Laurent|||0000-0003-0548-2486
  • Tifft, Eric|||0000-0002-7480-0276
  • Vallada, Homero|||0000-0001-5123-8295
  • van Kirk, Nathanial|||0000-0002-1975-4238
  • Veenstra-VanderWeele, Jeremy|||0000-0002-6349-1076
  • Vulink, Nienke N.|||0000-0001-8991-9627
  • Walker, Christopher P.|||0000-0002-6069-0184
  • Wang, Ying
  • Wendland, Jens|||0000-0001-5106-5013
  • Winsvold, Bendik Slagsvold|||0000-0003-4171-8919
  • Yao, Yin|||0000-0001-7487-4294
  • Zhou, Hang|||0000-0002-7694-6391
  • Agrawal, Arpana|||0000-0002-0313-793X
  • Alonso, Pino|||0000-0002-5779-9111
  • Berberich, Götz|||0000-0001-8300-9294
  • Bucholz, Kathleen K.|||0000-0003-3794-0736
  • Bulik, Cynthia M.|||0000-0001-7772-3264
  • Cath, Danielle|||0000-0001-9539-4118
  • Denys, Damiaan|||0000-0002-3191-3844
  • Eapen, Valsamma|||0000-0001-6296-8306
  • Edenberg, Howard J.|||0000-0003-0344-9690
  • Falkai, Peter|||0000-0003-2873-8667
  • Fernandez, Thomas V.|||0000-0003-0830-022X
  • Fyer, Abby J.|||0000-0002-0944-2505
  • Geller, Dan A.|||0000-0001-8692-4156
  • Grabe, Hans J.|||0000-0003-3684-4208
  • Greenberg, Benjamin D.|||0000-0002-5648-0002
  • Hanna, Gregory L.|||0000-0002-0742-6990
  • Hickie, Ian B.|||0000-0001-8832-9895
  • Hougaard, David M.|||0000-0001-5928-3517
  • Kathmann, Norbert|||0000-0002-1348-7060
  • Kennedy, James L.|||0000-0002-8733-3806
  • Lai, Dongbing|||0000-0001-7803-580X
  • Landén, Mikael|||0000-0002-4496-6451
  • Le Hellard, Stéphanie|||0000-0002-8085-051X
  • Leboyer, Marion|||0000-0001-5473-3697
  • Lochner, Christine|||0000-0002-4766-3704
  • McCracken, James T.|||0000-0003-0370-0777
  • Medland, Sarah Elizabeth|||0000-0003-1382-380X
  • Mortensen, Preben Bo|||0000-0002-5230-9865
  • Neale, Benjamin M.|||0000-0003-1513-6077
  • Nicolini, Humberto|||0000-0003-2494-0067
  • Nordentoft, Merete|||0000-0003-4895-7023
  • Pato, Michele
  • Pato, Carlos|||0000-0002-5858-266X
  • Pauls, David L.|||0000-0002-8107-345X
  • Piacentini, John|||0000-0003-4195-7194
  • Pittenger, Christopher|||0000-0003-2117-9321
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Rasmussen, Steven A.|||0000-0002-8327-0692
  • Richter, Margaret A.|||0000-0001-5450-2936
  • Rosenberg, David R.|||0000-0002-0005-4151
  • Ruhrmann, Stephan|||0000-0002-6022-2364
  • Samuels, Jack F.|||0000-0002-6715-7905
  • Sandin, Sven|||0000-0001-6994-4884
  • Sandor, Paul|||0000-0003-2397-0758
  • Spalletta, Gianfranco|||0000-0002-7432-4249
  • Stein, Dan J.|||0000-0001-7218-7810
  • Stewart, S. Evelyn|||0000-0002-0994-6383
  • Storch, Eric A.|||0000-0002-7631-3703
  • Stranger, Barbara E.|||0000-0001-9021-7331
  • Turiel, Maurizio|||0000-0002-8793-2112
  • Werge, Thomas|||0000-0003-1829-0766
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Børglum, Anders D.|||0000-0001-8627-7219
  • Walitza, Susanne|||0000-0002-8161-8683
  • Hveem, Kristian|||0000-0001-8157-9744
  • Hansen, Bjarne K.|||0000-0001-5659-1119
  • Rück, Christian P.|||0000-0002-8742-0168
  • Martin, Nicholas G.|||0000-0003-4069-8020
  • Milani, Lili|||0000-0002-5323-3102
  • Mors, Ole|||0000-0002-5660-0393
  • Reichborn-Kjennerud, Ted|||0000-0003-4653-0034
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Kvale, Gerd|||0000-0001-5449-2344
  • Mataix-Cols, David|||0000-0002-4545-0924
  • Domschke, Katharina|||0000-0002-2550-9132
  • Grünblatt, Edna|||0000-0001-8505-7265
  • Wagner, Michael
  • Zwart, John-Anker|||0000-0001-5721-0154
  • Breen, Gerome|||0000-0003-2053-1792
  • Nestadt, Gerald|||0000-0001-9461-5249
  • Kaprio, Jaakko|||0000-0002-3716-2455
  • Arnold, Paul D.|||0000-0003-2496-4624
  • Grice, Dorothy E.|||0000-0002-8833-2549
  • Knowles, James A.|||0000-0002-3307-5741
  • Ask, Helga|||0000-0003-0149-5319
  • Verweij, Karin|||0000-0001-9868-7821
  • Davis, Lea K.|||0000-0001-5143-2282
  • Smit, Dirk J.|||0000-0001-8301-8860
  • Crowley, James J.|||0000-0001-9051-1557
  • Scharf, Jeremiah M.|||0000-0002-4742-5896
  • Stein, Murray B.|||0000-0001-9564-2871
  • Gelernter, Joel|||0000-0002-4067-1859
  • Mathews, Carol A.|||0000-0003-2208-7058
  • Derks, Eske M.|||0000-0002-6292-6883
  • Mattheisen, Manuel|||0000-0002-8442-493X
Obsessive-compulsive disorder (OCD) affects ~1% of children and adults and is partly caused by genetic factors. We conducted a genome-wide association study (GWAS) meta-analysis combining 53,660 OCD cases and 2,044,417 controls and identified 30 independent genome-wide significant loci. Gene-based approaches identified 249 potential effector genes for OCD, with 25 of these classified as the most likely causal candidates, including WDR6, DALRD3 and CTNND1 and multiple genes in the major histocompatibility complex (MHC) region. We estimated that ~11,500 genetic variants explained 90% of OCD genetic heritability. OCD genetic risk was associated with excitatory neurons in the hippocampus and the cortex, along with D and D type dopamine receptor-containing medium spiny neurons. OCD genetic risk was shared with 65 of 112 additional phenotypes, including all the psychiatric disorders we examined. In particular, OCD shared genetic risk with anxiety, depression, anorexia nervosa and Tourette syndrome and was negatively associated with inflammatory bowel diseases, educational attainment and body mass index.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans

  • Sønderby, Ida E.
  • van der Meer, Dennis
  • Moreau, Clara
  • Kaufmann, Tobias
  • Bragi Walters, G.
  • Ellegaard, Maria
  • Abdellaoui, Abdel
  • Ames, David
  • Amunts, Katrin
  • Andersson, Micael
  • Armstrong, Nicola J.
  • Modenato, Claudia
  • Monereo Sánchez, Jennifer
  • Morris, Derek W.
  • Mühleisen, Thomas W.
  • Pausova, Zdenka
  • Olde Loohuis, Loes M.
  • Peralta, Juan M.
  • Pike, G. Bruce
  • Prieto, Carlos
  • Quinlan, Erin B.
  • Wright, Margaret J.
  • Reinbold, Céline S.
  • Stefansson, Hreinn
  • Reis Marques, Tiago
  • Bernard, Manon
  • Rucker, James J. H.
  • Sachdev, Perminder S.
  • Sando, Sigrid B.
  • Schofield, Peter R.
  • Schork, Andrew J.
  • Schumann, Gunter
  • Agartz, Ingrid
  • Shin, Jean
  • Shumskaya, Elena
  • Stefansson, Kari
  • Silva, Ana I.
  • Sisodiya, Sanjay M.
  • Blackburn, Nicholas B.
  • Steen, Vidar M.
  • Stein, Dan J.
  • Strike, Lachlan T.
  • Suzuki, Ikuo K.
  • Djurovic, Srdjan
  • Tamnes, Christian K.
  • Teumer, Alexander
  • Thalamuthu, Anbupalam
  • Jacquemont, Sébastien
  • Tordesillas-Gutiérrez, Diana
  • Uhlmann, Anne
  • Ulfarsson, Magnus O.
  • Blangero, John
  • van't Ent, Dennis
  • van den Bree, Marianne B. M.
  • Westlye, Lars T.
  • Vanderhaeghen, Pierre
  • Vassos, Evangelos
  • Wen, Wei
  • Wittfeld, Katharina
  • Thompson, Paul M.
  • Boomsma, Dorret I.
  • Andreassen, Ole A.
  • Brodaty, Henry
  • Brouwer, Rachel M.
  • Bülow, Robin
  • Bøen, Rune
  • Groenewold, Nynke A.
  • Cahn, Wiepke
  • Hashimoto, Ryota
  • Calhoun, Vincent
  • Caspers, Svenja
  • Ching, Christopher R. K.
  • Cichon, Sven
  • Ciufolini, Simone
  • Crespo-Facorro, Benedicto
  • Curran, Joanne E.
  • Dale, Anders M.
  • Gústafsson, Ómar
  • Dalvie, Shareefa
  • Dazzan, Paola
  • Hehir-Kwa, Jayne Y.
  • de Geus, de Geus,
  • Zubicaray, Greig I. de
  • de Zwarte, Sonja M. C.
  • Desrivieres, Sylvane
  • Doherty, Joanne L.
  • Donohoe, Gary
  • Draganski, Bogdan
  • Haavik, Jan
  • Ehrlich, Stefan
  • Eising, Else
  • Espeseth, Thomas
  • Hibar, Derrek P.
  • Fejgin, Kim
  • Fisher, Simon E.
  • Fladby, Tormod
  • Frei, Oleksandr
  • Frouin, Vincent
  • Fukunaga, Masaki
  • Haberg, Asta K.
  • Gareau, Thomas
  • Ge,Tian
  • Glahn, David C.
  • Grabe, Hans-Jörgen
  • Hillegers, Manon H. J.
  • Hall, Jeremy
  • Hoffmann, Per
  • Holleran, Laurena
  • Holmes, Avram J.
  • Homuth, Georg
  • Hottenga, Jouke-Jan
  • Murray, Robin M.
  • Hulshoff Pol, Hilleke E.
  • Ophoff, Roel A.
  • Ikeda, Masashi
  • Jahanshad, Neda
  • Jockwitz, Christiane
  • Johansson, Stefan
  • Jönsson, Erik G.
  • Jørgensen, Niklas R.
  • Kikuchi, Masataka
  • Knowles, Emma E. M.
  • Nielsen, Jacob
  • Kumar, Kuldeep
  • Le Hellard, Stephanie
  • Owen, Michael J.
  • Leu, Costin
  • Linden, David E. J.
  • Liu, Jingyu
  • Lundervold, Arvid
  • Lundervold, Astri Johansen
  • Maillard, Anne M.
  • Martin, Nicholas G.
  • Nordvik, Jan E.
  • Martin-Brevet, Sandra
  • Mather, Karen A.
  • Mathias, Samuel R.
  • Paus, Tomas
  • McMahon, Katie L.
  • McRae, Allan F.
  • Medland, Sarah E.
  • Meyer-Lindenberg, Andreas
  • Moberget,
  • Torgeir
  • Nyberg, Lars
ENIGMA-CNV working group., Low-frequency 1q21.1 distal deletion and duplication copy number variant (CNV) carriers are predisposed to multiple neurodevelopmental disorders, including schizophrenia, autism and intellectual disability. Human carriers display a high prevalence of micro- and macrocephaly in deletion and duplication carriers, respectively. The underlying brain structural diversity remains largely unknown. We systematically called CNVs in 38 cohorts from the large-scale ENIGMA-CNV collaboration and the UK Biobank and identified 28 1q21.1 distal deletion and 22 duplication carriers and 37,088 non-carriers (48% male) derived from 15 distinct magnetic resonance imaging scanner sites. With standardized methods, we compared subcortical and cortical brain measures (all) and cognitive performance (UK Biobank only) between carrier groups also testing for mediation of brain structure on cognition. We identified positive dosage effects of copy number on intracranial volume (ICV) and total cortical surface area, with the largest effects in frontal and cingulate cortices, and negative dosage effects on caudate and hippocampal volumes. The carriers displayed distinct cognitive deficit profiles in cognitive tasks from the UK Biobank with intermediate decreases in duplication carriers and somewhat larger in deletion carriers—the latter potentially mediated by ICV or cortical surface area. These results shed light on pathobiological mechanisms of neurodevelopmental disorders, by demonstrating gene dose effect on specific brain structures and effect on cognitive function., 1000BRAINS: The 1000BRAINS study was funded by the Institute of Neuroscience and Medicine, Research Center Juelich, Germany. We thank the Heinz Nixdorf Foundation (Germany) for the generous support of the Heinz Nixdorf Recall Study on which 1000BRAINS is based. We also thank the scientists and the study staff of the Heinz Nixdorf Recall Study and 1000BRAINS. Funding was also granted by the Initiative and Networking Fund of the Helmholtz Association (Caspers) and the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement 945539 (Human Brain Project SGA3; Amunts, Caspers, Cichon). Brainscale: The Brainscale study was supported by the Netherlands Organization for Scientific Research MagW 480-04-004 (Dorret I. Boomsma), 51.02.060 (Hilleke E. Hulshoff Pol), 668.772 (Dorret I. Boomsma and Hilleke E. Hulshoff Pol); NWO/SPI 56-464-14192 (Dorret I. Boomsma), the European Research Council (ERC-230374) (Dorret I. Boomsma), High Potential Grant Utrecht University (Hilleke E.Hulshoff Pol) and NWO Brain and Cognition 433-09-220 (Hilleke E.Hulshoff Pol). Betula: The Betula study was funded by the Knut and Alice Wallenberg (KAW) foundation (Nyberg). The Freesurfer segmentations on the Betula sample were performed on resources provided by the Swedish National Infrastructure for Computing (SNIC) at HPC2N (in Umeå, Sweden), partially funded by the Swedish Research Council through grant agreement no. 2018-05973. Brain Imaging Genetics (BIG): This work makes use of the BIG database, first established in Nijmegen, The Netherlands, in 2007. This resource is now part of Cognomics (www.cognomics.nl), a joint initiative by researchers from the Donders Centre for Cognitive Neuroimaging, the Human Genetics and Cognitive Neuroscience departments of the Radboud University Medical Centre and the Max Planck Institute for Psycholinguistics in Nijmegen. The Cognomics Initiative has received support from the participating departments and centres and from external grants, that is, the Biobanking and Biomolecular Resources Research Infrastructure (Netherlands) (BBMRI-NL), the Hersenstichting Nederland and the Netherlands Organization for Scientific Research (NWO). The research leading to these results also receives funding from the NWO Gravitation grant ‘Language in Interaction’, the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement nos. 602450 (IMAGEMEND), 278948 (TACTICS) and 602805 (Aggressotype), as well as from the European Community’s Horizon 2020 programme under grant agreement no. 643051 (MiND) and from ERC-2010-AdG 268800-NEUROSCHEMA. In addition, the work was supported by a grant for the ENIGMA Consortium (grant number U54 EB020403) from the BD2K Initiative of a cross-NIH partnership. deCODE genetics: deCODE genetics acknowledges support from the Innovative Medicines Initiative Joint Undertaking under grant agreement nos. 115008 (NEWMEDS) and 115300 (EUAIMS), of which resources are composed of EFPIA in-kind contribution and financial contribution from the European Union’s Seventh Framework Programme (EU-FP7/2007-2013), EU-FP7-funded grant agreement no. 602450 (IMAGEMEND) and EU-funded FP7-People-2011-IAPP grant agreement no. 286213 (PsychDPC). Dublin: This work was supported by Science Foundation Ireland (SFI grant 12/IP/1359 to Gary Donohoe and grant SFI08/IN.1/B1916-Corvin to Aidan C. Corvin). ECHO-DEFINE: The ECHO study acknowledges funding from a Medical Research Council (MRC) Centre Grant to Michael J. Owen (G0801418), the Wellcome Trust (Institutional Strategic Support Fund (ISSF) to van den Bree and Clinical Research Training Fellowship to Joanne L. Doherty), the Waterloo Foundation (WF 918-1234 to van den Bree), the Baily Thomas Charitable Fund (2315/1 to van den Bree), National Institute of Mental Health (NIMH 5UO1MH101724 to van den Bree and Michael J. Owen), the IMAGINE-2 study (funded by the MRC (MR/T033045/1) to van den Bree, Jeremy Hall and Michael J. Owen), the IMAGINE-ID study (funded by MRC (MR/N022572/1) to Jeremy Hall, van den Bree and Owen). The DEFINE study was supported by a Wellcome Trust Strategic Award (100202/Z/12/Z) to Michael J. Owen. ENIGMA: ENIGMA is supported in part by NIH grants U54 EB20403, R01MH116147 and R56AG058854. NIA T32AG058507; NIH/NIMH 5T32MH073526. EPIGEN-Dublin: The EPIGEN-Dublin cohort was supported by a Science Foundation Ireland Research Frontiers Programme award (08/RFP/GEN1538). EPIGEN-UK (Sisodiya): The work was partly undertaken at UCLH/UCL, which received a proportion of funding from the UK Department of Health’s NIHR Biomedical Research Centres funding scheme. We are grateful to the Wolfson Trust and the Epilepsy Society for supporting the Epilepsy Society MRI scanner. GAP: This work was supported by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, Psychology and Neuroscience, King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. GOBS: The GOBS study data collection was supported in part by the National Institutes of Health (NIH) grants: R01 MH078143, R01 MH078111 and R01 MH083824, with work conducted in part in facilities constructed under the support of NIH grant C06 RR020547. GSP: Data were in part provided by the Brain Genomics Superstruct Project (GSP) of Harvard University and Massachusetts General Hospital (MGH) (Principal Investigators: Randy Buckner, Jordan Smoller and Joshua Roffman), with support from the Center for Brain Science Neuroinformatics Research Group, Athinoula A. Martinos Center for Biomedical Imaging, Center for Genomic Medicine and Stanley Center for Psychiatric Research. Twenty individual investigators at Harvard and MGH generously contributed data to the overall project. We would like to thank Randy Buckner for insightful comments and feedback on this work. HUBIN: The HUBIN study was financed by the Swedish Research Council (K2010-62X-15078-07-2, K2012-61X-15078-09-3, 521-2014-3487 K2015-62X-15077-12-3, 2017-00949), the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet. HUNT: The HUNT study is a collaboration between HUNT Research Centre (Faculty of Medicine and Movement Sciences, NTNU—Norwegian University of Science and Technology), Nord-Trøndelag County Council, Central Norway Health Authority and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology, and the Norwegian National Advisory Unit for functional MRI. IMAGEN: This work received support from the following sources: the European Union-funded FP6 Integrated Project IMAGEN (reinforcement-related behaviour in normal brain function and psychopathology) (LSHM-CT- 2007-037286), the Horizon 2020 funded ERC Advanced Grant ‘STRATIFY’ (Brain network based stratification of reinforcement-related disorders) (695313), ERANID (Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways) (PR-ST-0416-10004), BRIDGET (JPND: BRain Imaging, cognition Dementia and next generation GEnomics) (MR/N027558/1), Human Brain Project (HBP SGA 2, 785907),the FP7 projects IMAGEMEND(602450; IMAging GEnetics for MENtal Disorders) and MATRICS (603016), the Innovative Medicine Initiative Project EUAIMS (115300-2), the Medical Research Council Grant ‘c-VEDA’ (Consortium on Vulnerability to Externalizing Disorders and Addictions) (MR/N000390/1), the Swedish Research Council FORMAS, the Medical Research Council, the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, the Bundesministeriumfür Bildung und Forschung (BMBF grants 01GS08152, 01EV0711; eMED SysAlc01ZX1311A; Forschungsnetz AERIAL 01EE1406A, 01EE1406B), the Deutsche Forschungsgemeinschaft (DFG grants, SM 80/7-2, SFB 940/2), the Medical Research Foundation and Medical Research Council (grants MR/R00465X/1 and MR/S020306/1). Further support was provided by grants from: ANR (project AF12-NEUR0008-01—WM2NA, ANR-12-SAMA-0004), the Eranet Neuron (ANR-18-NEUR00002-01), the Fondation de France (00081242), the Fondation pour la Recherche Médicale (DPA20140629802), the Mission Interministérielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives (MILDECA), the Assistance-Publique-Hôpitaux-de-Paris and INSERM (interface grant), Paris Sud University IDEX 2012, the Fondation de l’Avenir (grant AP-RM-17-013), the Fédération pour la Recherche sur le Cerveau; the National Institutes of Health, Science Foundation Ireland (16/ERCD/3797), USA (Axon, Testosterone and Mental Health during Adolescence; RO1 MH085772-01A1) and by NIH Consortium grant U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence. Lifespan: The study is funded by the Research Council of Norway (230345, 288083 and 223273). NCNG: NCNG sample collection was supported by grants from the Bergen Research Foundation and the University of Bergen, the Dr Einar Martens Fund, the Research Council of Norway, to le Hellard, Steen and Espeseth. The Bergen group was supported by grants from the Western Norway Regional Health Authority (Grant 911593 to Arvid Lundervold, Grant 911397 and 911687 to Astri Johansen Lundervold). NTR: The NTR cohort was supported by the Netherlands Organization for Scientific Research (NWO) and The Netherlands Organisation for Health Research and Development (ZonMW) grants 904-61-090, 985-10-002, 912-10-020, 904-61-193, 480-04-004,463-06-001, 451-04-034, 400-05-717, Addiction-31160008, 016-115-035, 481-08-011, 056-32-010, Middelgroot-911-09-032, OCW_NWO Gravity programme—024.001.003, NWO-Groot 480-15-001/674, Center for Medical Systems Biology (CSMB, NWO Genomics), NBIC/BioAssist/RK(2008.024), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL, 184.021.007 and 184.033.111); Spinozapremie (NWO-56-464-14192), KNAW Academy Professor Award (PAH/6635) and University Research Fellow grant (URF) to Dorret I. Boomsma; Amsterdam Public Health research institute (former EMGO+), Neuroscience Amsterdam research institute (former NCA); the European Science Foundation (ESF, EU/QLRT-2001-01254), the European Community’s Seventh Framework Programme (FP7- HEALTH-F4-2007-2013, grant 01413: ENGAGE and grant 602768: ACTION); the European Research Council (ERC Starting 284167, ERC Consolidator 771057, ERC Advanced 230374), Rutgers University Cell and DNA Repository (NIMH U24 MH068457-06), the National Institutes of Health (NIH, R01D0042157-01A1, R01MH58799-03, MH081802, DA018673, R01 DK092127-04, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995); the Avera Institute for Human Genetics, Sioux Falls, South Dakota (USA). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. Computing was supported by NWO through grant 2018/EW/00408559, BiG Grid, the Dutch e-Science Grid and SURFSARA. OATS: The OATS study has been funded by a National Health & Medical Research Council (NHMRC) and Australian Research Council (ARC) Strategic Award Grant of the Ageing Well, Ageing Productively Programme (ID No. 401162) and NHMRC Project Grants (ID Nos. 1045325 and 1085606). This research was facilitated through Twins Research Australia, a national resource in part supported by an NHMRC Centre for Research Excellence Grant (ID No.: 1079102). We thank the participants for their time and generosity in contributing to this research. We acknowledge the contribution of the OATS research team (https://cheba.unsw.edu.au/project/older-australian-twins-study) to this study. OATS genotyping was partly funded by a Commonwealth Scientific and Industrial Research Organization Flagship Collaboration Fund Grant. Osaka: Osaka study was supported by the Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS: Grant Number JP18dm0207006), Brain/MINDS& beyond studies (Grant Number JP20dm0307002) and Health and Labour Sciences Research Grants for Comprehensive Research on Persons with Disabilities (Grant Number JP20dk0307081) from the Japan Agency for Medical Research and Development (AMED), Grants-in-Aid for Scientific Research (KAKENHI; Grant Numbers JP25293250 and JP16H05375). Some computations were performed at the Research Center for Computational Science, Okazaki, Japan. PAFIP: The PAFIP study was supported by Instituto de Salud Carlos III, FIS 00/3095, 01/3129, PI020499, PI060507, PI10/00183, the SENY Fundació Research Grant CI2005-0308007 and the FundaciónMarqués de Valdecilla API07/011. Biological samples from our cohort were stored at the Valdecilla Biobank and genotyping services were conducted at the Spanish ‘Centro Nacional de Genotipado’ (CEGEN-ISCIII). MCIC/COBRE: The study is funded by the National Institutes of Health studies R01EB006841, P20GM103472 and P30GM122734 and Department of Energy DE-FG02-99ER62764. PING: Data collection and sharing for the Paediatric Imaging, Neurocognition and Genetics (PING) Study (National Institutes of Health Grant RC2DA029475) were funded by the National Institute on Drug Abuse and the Eunice Kennedy Shriver National Institute of Child Health & Human Development. A full list of PING investigators is at http://pingstudy.ucsd.edu/investigators.html. QTIM: The QTIM study was supported by the National Institute of Child Health and Human Development (R01 HD050735) and the National Health and Medical Research Council (NHMRC 486682, 1009064), Australia. Genotyping was supported by NHMRC (389875). Medland is supported in part by an NHMRC fellowship (APP1103623). SHIP: SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grant nos. 01ZZ9603, 01ZZ0103 and 01ZZ0403), the Ministry of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide single-nucleotide polymorphism typing in SHIP and MRI scans in SHIP and SHIP-TREND have been supported by a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. StrokeMRI: StrokeMRI was supported by the Norwegian ExtraFoundation for Health and Rehabilitation(2015/FO5146), the Research Council of Norway (249795, 262372), the South-Eastern Norway Regional Health Authority (2014097, 2015044, 2015073) and the Department of Psychology, University of Oslo. Sydney MAS: The Sydney Memory and Aging Study (Sydney MAS) is funded by National and HealthMedical Research Council (NHMRC) Programme and Project Grants (ID350833, ID568969 and ID109308). We also thank the Sydney MAS participants and the Research Team. SYS: The SYS Study is supported by Canadian Institutes of Health Research. TOP: Centre of Excellence: RCN #23273 and RCN #226971. Part of this work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT-Department (USIT) (tsd-drift@usit.uio.no). The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7-PEOPLE-2013-COFUND) under grant agreement no. 609020—Scientia Fellows; the Research Council of Norway (RCN) #276082—A lifespan perspective on mental illness: toward precision medicine using multimodal brain imaging and genetics. Ida E. Sønderby and Rune Bøen are supported by South-Eastern Norway Regional Health Authority (#2020060). Ida E. Sønderby and Ole A. Andreassen have received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant agreement no. 847776 (CoMorMent project) and the KG Jebsen Foundation (SKGJ-MED-021). UCLA_UMCU: The UCLA_UMCU cohort comprises of six studies which were supported by National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD) (20244 to Prof. Hillegers), The Netherlands Organisation for Health Research and Development (ZonMw) (908-02-123 to Prof. Hulshoff Pol), and Netherlands Organisation for Scientific Research (NWO 9120818 and NWO-VIDI 917-46-370 to Prof. Hulshoff Pol). The GROUP study was funded through the Geestkracht programme of the Dutch Health Research Council (ZonMw, grant number 10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly and Janssen Cilag) and universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ inGeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord-Holland-Noord. Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia Psycho-medical Center, The Hague. Maastricht: Maastricht University Medical Centre and the mental health institutions: GGzE, GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh, voor Geestelijke Gezondheid, Mondriaan, Virenzeriagg, Zuyderland GGZ, MET ggz, Universitair Centrum Sint-JozefKortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem. Utrecht: University Medical Center Utrecht and the mental health institutions: Altrecht, GGZ Centraal and Delta.). UK Biobank: This work made use of data sharing from UK Biobank (under project code 27412). Others: Work by Pierre Vanderhaeghen was funded by Grants of the European Research Council (ERC Adv Grant GENDEVOCORTEX), the EOS Programme, the Belgian FWO, the AXA Research Fund and the Belgian Queen Elizabeth Foundation. Ikuo K. Suzuki was supported by a postdoctoral fellowship of the FRS/FNRS., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genetic variants associated with longitudinal changes in brain structure across the lifespan

  • Brouwer, Rachel M.
  • Tordesillas-Gutiérrez, Diana
  • Crespo-Facorro, Benedicto
  • Hulshoff Pol, Hilleke E.
et al., Human brain structure changes throughout the lifespan. Altered brain growth or rates of decline are implicated in a vast range of psychiatric, developmental and neurodegenerative diseases. In this study, we identified common genetic variants that affect rates of brain growth or atrophy in what is, to our knowledge, the first genome-wide association meta-analysis of changes in brain morphology across the lifespan. Longitudinal magnetic resonance imaging data from 15,640 individuals were used to compute rates of change for 15 brain structures. The most robustly identified genes GPR139, DACH1 and APOE are associated with metabolic processes. We demonstrate global genetic overlap with depression, schizophrenia, cognitive functioning, insomnia, height, body mass index and smoking. Gene set findings implicate both early brain development and neurodegenerative processes in the rates of brain changes. Identifying variants involved in structural brain changes may help to determine biological pathways underlying optimal and dysfunctional brain development and aging., The ENIGMA-Plasticity Working Group is part of the ENIGMA World Aging Center, funded by NIA grants R56 AG058854 and R01 AG058854. The ENIGMA Consortium core funding was supported by NIH Consortium Grant U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centers of Excellence. 1000BRAINS: 1000BRAINS is a population-based cohort based on the Heinz-Nixdorf Recall Study and is supported, in part, by the German National Cohort. We thank the Heinz Nixdorf Foundation (Germany) for their generous support in terms of the Heinz Nixdorf Study. The authors are supported by the Initiative and Networking Fund of the Helmholtz Association (Svenja Caspers) and the European Union’s Horizon 2020 Research and Innovation Programme under grant agreements 785907 (Human Brain Project SGA2; Svenja Caspers, Sven Cichon and Katrin Amunts). This work was further supported by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders) under the auspices of the e:Med Program (grant 01ZX1314A; Sven Cichon) and by the Swiss National Science Foundation (SNSF, grant 156791; Sven Cichon). The authors acknowledge grants supporting their work from the European Union’s Horizon 2020 Research and Innovation Programme (H2020/2014–2020) under grant agreements 667302 (CoCA), 728018 (Eat2beNICE), 785907 (HBP SGA2) and 772376 (EScORIAL) and the Netherlands ALS Foundation.Additional support is received from the European Community’s Seventh Framework Programme (FP7/2007—2013) under grant agreements n° 602805 (Aggressotype), n° 603016 (MATRICS), n° 602450 (IMAGEMEND) and n° 278948 (TACTICS) and from the European Community’s Horizon 2020 Programme (H2020/2014—2020) under grant agreements n° 643051 (MiND) and n° 667302 (CoCA). FP7 Ideas: the European Research Council (ERC-230374 to D.B.). This work was supported by Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012 and PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds; European Union Seventh Framework Program under grant agreements FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement 115916, Project PRISM and grant agreement 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. The Horizon 2020 funded ERC Advanced Grant ‘STRATIFY’ (Brain network based stratification of reinforcement-related disorders) (695313). The FP7 project MATRICS (603016). The research leading to these results also received support from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement 278948 (TACTICS), 602805 (Aggressotype), 603016 (MATRICS) and 602450 (Imagemend) and the Innovation Medicine Initiative grants 115300 (EU-AIMS) and 777394 (AIMS-2-TRIALS).PAFIP: PAFIP was supported by the Instituto de Salud Carlos III (PI14/00639, PI14/00918 and PI17/01056) and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT025KG Jebsen Stiftelsen and H2020 CoMorMent (847776).34363). European Union Marie Curie Research Training Network (MRTN-CT-2006-035987)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia

  • Pardiñas, Antonio F.
  • Smart, Sophie E.
  • Willcocks, Isabella R.
  • Holmans, Peter A.
  • Dennison, Charlotte A.
  • Lynham, Amy
  • Legge, Sophie E.
  • Baune, Bernhard T.
  • Bigdeli, Tim B.
  • Cairns, Murray J.
  • Corvin, Aiden
  • Fanous, Ayman H.
  • Frank, Josef
  • Kelly, Brian
  • McQuillin, Andrew
  • Melle, Ingrid
  • Mortensen, Preben B.
  • Mowry, Bryan J.
  • Pato, Carlos N.
  • Periyasamy, Sathish
  • Rietschel, Marcella
  • Rujescu, Dan
  • Simonsen, Carmen
  • St Clair, David
  • Tooney, Paul A.
  • Wu, Jing Qin
  • Andreassen, Ole A.
  • Kowalec, Kaarina
  • Sullivan, Patrick F.
  • Murray, Robin M.
  • Owen, Michael J.
  • MacCabe, James H.
  • O'Donovan, Michael C.
  • Walters, James T. R.
  • Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances (STRATA)
  • Consortium and the Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC)
[Importance] About 20% to 30% of people with schizophrenia have psychotic symptoms that do not respond adequately to first-line antipsychotic treatment. This clinical presentation, chronic and highly disabling, is known as treatment-resistant schizophrenia (TRS). The causes of treatment resistance and their relationships with causes underlying schizophrenia are largely unknown. Adequately powered genetic studies of TRS are scarce because of the difficulty in collecting data from well-characterized TRS cohorts., [Objective] To examine the genetic architecture of TRS through the reassessment of genetic data from schizophrenia studies and its validation in carefully ascertained clinical samples., [Design, Setting, and Participants] Two case-control genome-wide association studies (GWASs) of schizophrenia were performed in which the case samples were defined as individuals with TRS (n = 10 501) and individuals with non-TRS (n = 20 325). The differences in effect sizes for allelic associations were then determined between both studies, the reasoning being such differences reflect treatment resistance instead of schizophrenia. Genotype data were retrieved from the CLOZUK and Psychiatric Genomics Consortium (PGC) schizophrenia studies. The output was validated using polygenic risk score (PRS) profiling of 2 independent schizophrenia cohorts with TRS and non-TRS: a prevalence sample with 817 individuals (Cardiff Cognition in Schizophrenia [CardiffCOGS]) and an incidence sample with 563 individuals (Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances [STRATA-G])., [Main Outcomes and Measures] GWAS of treatment resistance in schizophrenia. The results of the GWAS were compared with complex polygenic traits through a genetic correlation approach and were used for PRS analysis on the independent validation cohorts using the same TRS definition., [Results] The study included a total of 85 490 participants (48 635 [56.9%] male) in its GWAS stage and 1380 participants (859 [62.2%] male) in its PRS validation stage. Treatment resistance in schizophrenia emerged as a polygenic trait with detectable heritability (1% to 4%), and several traits related to intelligence and cognition were found to be genetically correlated with it (genetic correlation, 0.41-0.69). PRS analysis in the CardiffCOGS prevalence sample showed a positive association between TRS and a history of taking clozapine (r2 = 2.03%; P = .001), which was replicated in the STRATA-G incidence sample (r2 = 1.09%; P = .04)., [Conclusions and Relevance] In this GWAS, common genetic variants were differentially associated with TRS, and these associations may have been obscured through the amalgamation of large GWAS samples in previous studies of broadly defined schizophrenia. Findings of this study suggest the validity of meta-analytic approaches for studies on patient outcomes, including treatment resistance., This work was supported by Medical Research Council Centre grant MR/L010305/1, Medical Research Council Program grant MR/P005748/1, and Medical Research Council Project grants MR/L011794/1 and MC_PC_17212 to Cardiff University and by the National Centre for Mental Health, funded by the Welsh Government through Health and Care Research Wales. This work acknowledges the support of the Supercomputing Wales project, which is partially funded by the European Regional Development Fund via the Welsh Government. Dr Pardiñas was supported by an Academy of Medical Sciences Springboard Award (SBF005\1083). Dr Andreassen was supported by the Research Council of Norway (grants 283798, 262656, 248980, 273291, 248828, 248778, and 223273); KG Jebsen Stiftelsen, South-East Norway Health Authority, and the European Union’s Horizon 2020 Research and Innovation Programme (grant 847776). Dr Ajnakina was supported by an National Institute for Health Research postdoctoral fellowship (PDF-2018-11-ST2-020). Dr Joyce was supported by the University College London Hospitals/UCL University College London Biomedical Research Centre. Dr Kowalec received funding from the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement (793530) from the government of Canada Banting postdoctoral fellowship programme and the University of Manitoba. Dr Sullivan was supported by the Swedish Research Council (Vetenskapsrådet, D0886501), the European Union’s Horizon 2020 programme (COSYN, 610307) and the US National Institute of Mental Health (U01 MH109528 and R01 MH077139). The Psychiatric Genomics Consortium was partly supported by the National Institute Of Mental Health (grants R01MH124873). The Sweden Schizophrenia Study was supported by the National Institute Of Mental Health (grant R01MH077139). The STRATA consortium was supported by a Stratified Medicine Programme grant to Dr MacCabe from the Medical Research Council (grant MR/L011794/1), which funded the research and supported Drs Pardiñas, Smart, Kassoumeri, Murray, Walters, and MacCabe. Dr Smart was supported by a Collaboration for Leadership in Applied Health Research and Care South London at King’s College Hospital National Health Service Foundation Trust. The AESOP (US) cohort was funded by the UK Medical Research Council (grant G0500817). The Belfast (UK) cohort was funded by the Research and Development Office of Northern Ireland. The Bologna (Italy) cohort was funded by the European Community’s Seventh Framework program (HEALTH-F2-2010–241909, project EU-GEI). The Genetics and Psychosis project (London, UK) cohort was funded by the UK National Institute of Health Research Specialist Biomedical Research Centre for Mental Health, South London and the Maudsley National Health Service Mental Health Foundation Trust (SLAM) and the Institute of Psychiatry, Psychology, and Neuroscience at King’s College London; Psychiatry Research Trust; Maudsley Charity Research Fund; and the European Community’s Seventh Framework program (HEALTH-F2-2009-241909, project EU-GEI). The Lausanne (Switzerland) cohort was funded by the Swiss National Science Foundation (grants 320030_135736/1, 320030-120686, 324730-144064, 320030-173211, and 171804); the National Center of Competence in Research Synaptic Bases of Mental Diseases from the Swiss National Science Foundation (grant 51AU40_125759); and Fondation Alamaya. The Oslo (Norway) cohort was funded by the Research Council of Norway (grant 223273/F50, under the Centers of Excellence funding scheme, 300309, 283798) and the South-Eastern Norway Regional Health Authority (grants 2006233, 2006258, 2011085, 2014102, 2015088, and 2017-112). The Paris (France) cohort was funded by European Community’s Seventh Framework program (HEALTH-F2-2010–241909, project EU-GEI). The Prague (Czech Republic) cohort was funded by the Ministry of Health of the Czech Republic (grant NU20-04-00393). The Santander (Spain) cohort was funded by the following grants to Dr Crespo-Facorro: Instituto de Salud Carlos III (grants FIS00/3095, PI020499, PI050427, and PI060507), Plan Nacional de Drogas Research (grant 2005-Orden sco/3246/2004), SENY Fundatio Research (grant 2005-0308007), Fundacion Marques de Valdecilla (grant A/02/07, API07/011) and Ministry of Economy and Competitiveness and the European Fund for Regional Development (grants SAF2016-76046-R and SAF2013-46292-R). The West London (UK) cohort was funded by The Wellcome Trust (grants 042025, 052247, and 064607)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Beyond the global brain differences: Intraindividual variability differences in 1q21.1 distal and 15q11.2 BP1-BP2 deletion carriers

  • Boen, Rune
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
Rune Boen, et al., [Background]: Carriers of the 1q21.1 distal and 15q11.2 BP1-BP2 copy number variants exhibit regional and global brain differences compared with noncarriers. However, interpreting regional differences is challenging if a global difference drives the regional brain differences. Intraindividual variability measures can be used to test for regional differences beyond global differences in brain structure., [Methods]: Magnetic resonance imaging data were used to obtain regional brain values for 1q21.1 distal deletion (n = 30) and duplication (n = 27) and 15q11.2 BP1-BP2 deletion (n = 170) and duplication (n = 243) carriers and matched noncarriers (n = 2350). Regional intra-deviation scores, i.e., the standardized difference between an individual's regional difference and global difference, were used to test for regional differences that diverge from the global difference., [Results]: For the 1q21.1 distal deletion carriers, cortical surface area for regions in the medial visual cortex, posterior cingulate, and temporal pole differed less and regions in the prefrontal and superior temporal cortex differed more than the global difference in cortical surface area. For the 15q11.2 BP1-BP2 deletion carriers, cortical thickness in regions in the medial visual cortex, auditory cortex, and temporal pole differed less and the prefrontal and somatosensory cortex differed more than the global difference in cortical thickness., [Conclusions]: We find evidence for regional effects beyond differences in global brain measures in 1q21.1 distal and 15q11.2 BP1-BP2 copy number variants. The results provide new insight into brain profiling of the 1q21.1 distal and 15q11.2 BP1-BP2 copy number variants, with the potential to increase understanding of the mechanisms involved in altered neurodevelopment., 1000BRAINS. This work was supported by the Institute of Neuroscience and Medicine (INM-1), Research Centre Julich, European Union’s Horizon 2020 Research and Innovation Programme (Grant No. 945539 [HBP SGA3; SC]), and Joint Lab Supercomputing and Modeling for the Human Brain. We thank the Heinz Nixdorf Foundation for the generous support of the Heinz Nixdorf Study. We also thank the scientists and the study staff of the Heinz Nixdorf Recall Study and 1000BRAINS. We gratefully acknowledge the computing time granted through JARA-HPC on the supercomputer JURECA at Forschungszentrum Julich. TOP: This work was supported by Research Council of Norway (Grant Nos. 23273 (Centre of Excellence, Norwegian Centre for Mental Disorders, NORMENT), Grant Nos. 324252 and 226971). ENIGMA-CNV Working Group. This work was supported by the Research Council of Norway (Grant No. 223273 [to OAA]), South-Eastern Norway Regional Health Authority (Grant No. 2020060 [to IES, RB]), European Union’s Horizon 2020 Research and Innovation Programme (CoMorMent project; Grant No. 847776 [to IES]), Kristian Gerhard Jebsen Stiftelsen (Grant No. SKGJ-MED-021 [to IES]), and National Institute of Mental Health (NIMH) (Grant Nos. U01MH119736, R21MH116473, R01MH085953 [to CEB]), and 1R01MH129858-01A1 [to SJ]. This work was performed on Services for Sensitive Data, University of Oslo, with resources provided by UNINETT Sigma2, the national infrastructure for high performance computing and data storage in Norway. Australian Schizophrenia Research Bank: This work was supported by the Australian National Health and Medical Research Council (NHMRC) (Enabling Grant No. 386500, L3 Investigator Grant No. 1196508 [to CP]), and Program Grant No. APP1150083 [to CP]), Pratt Foundation, Ramsay Health Care, Viertel Charitable Foundation, and Schizophrenia Research Institute. Chief Investigators for the Australian Schizophrenia Research Bank were Vaughan Carr, US, RJS, Assen Jablensky, BJM, Patricia Michie, Stanley Catts, FAH, and CP. ECHO-DEFINE: This work was supported by the Wellcome Trust (Institutional Strategic Support Fund [to MBMvdB] and Clinical Research Training Fellowship Grant No. 102003/Z/13/Z [to JLD]), Waterloo Foundation (Grant No. WF 918-1234 [to MBMvdB]), Baily Thomas Charitable Fund (Grant No. 2315/1 [to MBMvdB]), NIMH (Grant Nos. 5UO1MH101724 and U01MH119738 [to MBMvdB]), IMAGINE-ID and IMAGINE-2 studies (funded by Medical Research Council Grant Nos. MR/N022572/1 and MR/T033045/1 [to MBMvdB]), and Medical Research Council (Centre Grant No. MR/P005748/1 [to MJO]). The DEFINE study was supported by a Wellcome Trust Strategic Award (Grant No. 100202/Z/12/Z [to MJO]). FOR2107 Marburg and Münster: This work is part of the German multicenter consortium “Neurobiology of Affective Disorders: A Translational Perspective on Brain Structure and Function,” supported by the German Research Foundation (Deutsche Forschungsgemeinschaft; Forschungsgruppe/Research Unit FOR2107). Principal investigators with respective areas of responsibility in the FOR2107 consortium: Work Package WP1, FOR2107/MACS cohort and brainimaging: TK (speaker FOR2107; DFG Grant Nos. KI 588/14-1, KI 588/14-2, KI 588/20-1, and KI 588/22-1), UD (co-speaker FOR2107; Grant Nos. DA 1151/5-1, DA 1151/5-2, and DA 1151/6-1), Axel Krug (Grant Nos. KR 3822/5-1 and KR 3822/7-2), IN (Grant Nos. NE 2254/1-2, NE 2254/3-1, and NE 2254/4-1), Carsten Konrad (Grant No. KO 4291/3-1). WP5, genetics: Marcella Rietschel (Grant Nos. RI 908/11-1 and RI 908/11-2), MMN (Grant Nos. NO 246/10-1 and NO 246/10-2), Stephanie Witt (Grant Nos. WI 3439/3-1 and WI 3439/3-2). WP6, multi-method data analytics: AJ (Grant Nos. JA 1890/7-1 and JA 1890/7-2), TH (Grant No. HA 7070/2-2). We are deeply indebted to all study participants and staff. A list of acknowledgments can be found at: www.for2107.de/acknowledgements. UCLA-Utrecht: This work was supported by the NIMH (Grant No. R01 MH090553 [to RAO]). The NIMH had no further role in study design, in the collection, analysis, and interpretation of the data, in the writing of the report, and in the decision to submit the paper for publication. QTIM: This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant No. R01 HD050735) and the NHMRC (Grant Nos. 486682 and 1009064). Genotyping was supported by the NHMRC (Grant No. 389875). BETULA: This work was supported by the Knut and Alice Wallenberg Foundation (scholar grant [to LN]). Freesurfer calculations were enabled by resources provided by the Swedish National Infrastructure for Computing at HPC2N, Umeå. SHIP (Study of Health in Pomerania): This work is part of the Community Medicine Research net of the University of Greifswald, Germany, which is supported by the Federal Ministry of Education and Research (Grant Nos. 01ZZ9603, 01ZZ0103, and 01ZZ0403), Ministry of Cultural Affairs, and Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide data in SHIP have been supported by the Federal Ministry of Education and Research (Grant No. 03ZIK012) and a joint grant from Siemens Healthineers and the Federal State of Mecklenburg-West Pomerania. MRI scans in SHIP and SHIP-TREND have been supported by a joint grant from Siemens Healthineers and the Federal State of Mecklenburg-West Pomerania. PAFIP (Programa de Atención a las Fases Iniciales de Psicosis): This work was supported by the Instituto de Salud Carlos III (Grant Nos. 00/3095, 01/3129, PI020499, PI14/00639, PI17/01056, and PI14/00918), SENY Fundació (Research Grant No. CI2005 0308007), and Fundación Marqués de Valdecilla Instituto de Investigación Sanitaria Valdecilla (Grant Nos. A/02/07, NCT0235832, and NCT02534363). Osaka: This work was supported by the Japan Agency for Medical Research and Development (Grant Nos. JP21wm0425012, JP18dm0307002, JP22wm0525019, and JP22dk0207060) and Japan Society for the Promotion of Science KAKENHI (Grant Nos. JP20H03611, JP22H04926, and 20K15778). Some computations were performed at the Research Center for Computational Science, Okazaki, Japan (Project: NIPS, 18-IMS-C162, 19-IMS-C181, 20-IMS-C162, 21-IMS-C179, 22-IMS-C195). IMAGEN: This work was supported by the European Union–funded FP6 Integrated Project IMAGEN (Reinforcement-Related Behavior in Normal Brain Function and Psychopathology) (Grant No. LSHM-CT-2007-037286), Horizon 2020–funded ERC Advanced Grant STRATIFY (Brain Network Based Stratification of Reinforcement-Related Disorders) (Grant No. 695313), Medical Research Foundation and Medical Research Council (Grants Nos. MR/R00465X/1 and MRF-058-0004-RG-DESRI [Neurobiological Underpinning of Eating Disorders: Integrative Biopsychosocial Longitudinal Analyses in Adolescents] and MR/S020306/1 and MRF-058-0009-RG-DESR-C0759 [Establishing Causal Relationships Between Biopsychosocial Predictors and Correlates of Eating Disorders and Their Mediation by Neural Pathways]), National Institutes of Health (NIH) (Consortium Grant No. U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence, and Grant No. 1R56AG058854-01), National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, ERANID (Understanding the Interplay Between Cultural, Biological and Subjective Factors in Drug Use Pathways) (Grant No. PR-ST-0416-10004), BRIDGET (JPND: BRain Imaging, cognition Dementia and next generation GEnomics) (Grant No. MR/N027558/1), Human Brain Project (HBP SGA 2) (Grant No. 785907), FP7 project MATRICS (Grant No. 603016), Medical Research Council Grant Consortium on Vulnerability to Externalizing Disorders and Addictions (Grant No. MR/N000390/1), Bundesministerium für Bildung und Forschung (Grant Nos. 01GS08152, 01EV0711, Forschungsnetz AERIAL 01EE1406A, and 01EE1406B), Deutsche Forschungsgemeinschaft (Grant Nos. SM 80/7-2, SFB 940/2, and NE 1383/14-1), Agence Nationale de la Recherche (ANR) (Grant Nos. ANR-12-SAMA-0004 and AAPG2019 [GeBra]), Eranet Neuron (Grant Nos. AF12-NEUR0008-01 [WM2NA], ANR-18-NEUR00002-01 [ADORe], and ANR-12-SAMA-0004), Fondation de France (Grant No. 00081242), Fondation pour la Recherche Médicale (Grant No. DPA20140629802), Mission Interministérielle de Lutte contre les Drogues et les Conduites Addictives, Assistance Publique Hôpitaux de Paris and Institut National de la Santé et de la Recherche Médicale (Interface Grant), Paris Sud University IDEX 2012, Fondation de l’Avenir (Grant No. AP-RM-17-013), and Fédération pour la Recherche sur le Cerveau. MCIC (Mind Clinical Imaging Consortium): This work was supported by the NIH (NIH/National Center for Research Resources Grant No. P41RR14075 [to VC] and Grant No. R01EB005846 [to VC]), Department of Energy (Grant No. DE-FG02-99ER62764), Mind Research Network, Morphometry Biomedical Informatics Research Network (Grant Nos. 1U24 and RR021382A), Function Biomedical Informatics Research Network (Grant No. U24RR021992-01 [to VC], NIH/National Center for Research Resources Grant No. MO1 RR025758-01 [to VC], and NIMH Grant No. 1RC1MH089257 [to VC]), Deutsche Forschungsgemeinschaft (research fellowship [to SE]), and Brain and Behavior Research Foundation (NARSAD Young Investigator Award [to SE]). NTR (Netherlands Twin Register): This work was supported by the Netherlands Organization for Scientific Research (NWO) and Netherlands Organisation for Health Research and Development (Grant Nos. 904-61-090, 985-10-002, 912-10-020, 904-61-193, 480-04-004,463-06-001, 451-04-034, 400-05-717, Addiction-31160008, 016-115-035, 481-08-011, 056-32-010, Middelgroot-911-09-032, OCW_NWO Gravity programme—024.001.003, and NWO-Groot 480-15-001/674), Center for Medical Systems Biology (NWO Genomics), NBIC/BioAssist/RK (Grant No. 2008.024), Biobanking and Biomolecular Resources Research Infrastructure The Netherlands (Grant Nos. 184.021.007 and 184.033.111), Spinozapremie (Grant No. NWO-56-464-14192), Royal Netherlands Academy of Arts and Sciences Academy Professor Award (Grant No. PAH/6635) and University Research Fellow grant (to DIB), Amsterdam Public Health research institute (former EMGO+ Institute for Health and Care Research), Amsterdam Neuroscience (former Neuoscience Campus Amsterdam), European Science Foundation (Grant No. EU/QLRT-2001-01254), European Community’s Seventh Framework Programme (FP7- HEALTH-F4-2007-2013, Grant Nos. 01413: ENGAGE and 602768: ACTION), European Research Council (Grant Nos. ERC Starting 284167, ERC Consolidator 771057, and ERC Advanced 230374), Rutgers University Cell and DNA Repository (NIMH Grant No. U24 MH068457-06), NIH (Grant Nos. R01D0042157-01A1, R01MH58799-03, MH081802, DA018673, and R01 DK092127-04 and Grand Opportunity Grant Nos. 1RC2 MH089951 and 1RC2 MH089995), and Avera Institute for Human Genetics. The genotyping and analyses were partly funded by the Genetic Association Information Network of the Foundation for the National Institutes of Health. Computing was supported by NWO (Grant No. 2018/EW/00408559), BiG Grid, Dutch e-Science Grid, and SURFsara. OATS (Older Australian Twins Study): This work was supported by the NHMRC and Australian Research Council Strategic Award Grant of the Ageing Well, Ageing Productively Program (Grant No. 401162), NHMRC project (seed) grants (Grant Nos. 1024224 and 1025243), NHMRC project grants (Grant Nos. 1045325 and 1085606), and NHMRC program grants (Grant Nos. 568969 and 1093083). The OATS Study was facilitated through access to Twins Research Australia, a national resource supported by a Centre of Research Excellence Grant (Grant No. 1079102) from the NHMRC. We thank the participants for their time and generosity in contributing to this research. We acknowledge the contribution of the OATS research team (https://cheba.unsw.edu.au/project/older-australian-twins-study) to this study. PING (Pediatric Imaging, Neurocognition, and Genetics): This work was supported by the National Institute on Drug Abuse and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant Nos. RC2DA029475 and R01 HD061414). EPIGEN-London/University College London: The work was partly undertaken at University College London Hospitals NHS Foundation Trust/University College London, which received a proportion of funding from the UK Department of Health National Institute for Health Research Biomedical Research Centres funding scheme. We thank the Wolfson Trust and the Epilepsy Society for supporting the Epilepsy Society MRI scanner. OSR (Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffele)-Milan: This work was supported by the European Union H2020 (EU.3.1.1 Grant No. 754740 MOODSTRATIFICATION.EU), Italian Ministry of Health (Grant No. RF-2018-12367249) and Italian Ministry of University and Scientific Research (Grant No. A_201779W93T). Dublin: This work was supported by the European Research Council (Grant No. ERC-2015-STG-677467 [to GD]) and Science Foundation Ireland (Grant No. SFI-16/ERCS/3787 [to GD]). Brain Imaging Genetics (BIG): This work makes use of the BIG database, first established in Nijmegen, the Netherlands, in 2007. This resource is now part of Cognomics (www.cognomics.nl), a joint initiative by researchers from the Donders Centre for Cognitive Neuroimaging, Human Genetics and Cognitive Neuroscience departments of Radboud University Medical Centre, and Max Planck Institute for Psycholinguistics in Nijmegen. The Cognomics Initiative is supported by the participating departments and centers and Biobanking and Biomolecular Resources Research Infrastructure (Netherlands), Hersenstichting Nederland, and NWO. The research leading to these results also receives funding from the NWO (Gravitation Grant No. 024.001.006 Language in Interaction), European Community’s Seventh Framework Programme (FP7/2007-2013) (Grant Nos. 602450 IMAGEMEND, 278948 TACTICS, and 602805 Aggressotype), European Community’s Horizon 2020 programme (Grant Nos. 643051 MiND, and ERC-2010-AdG 268800-NEUROSCHEMA). In addition, the work was supported by the ENIGMA Consortium (Grant No. U54 EB020403) from the BD2K Initiative of a cross-NIH partnership. UK Biobank: This research has been conducted using the UK Biobank Resource under Application Number 27412. OAA has received speaker’s honorarium from Lundbeck, Janssen, and Sunovion and is a consultant to Coretechs.ai. TRM reports personal fees from Pfizer, Lundbeck, Astellas, Janssen, and Angelini outside the submitted work. He is an employee and shareholder of Pasithea Therapeutics. CRKC has received partial research support from Biogen for work unrelated to the topic of this article (principal investigator, PMT). PMT has received partial research support from Biogen for work unrelated to the topic of this article. MBMvdB and MJO report grants from Takeda Pharmaceuticals outside the submitted work. MJO reports a grant from Akrivia Health outside the submitted work. HJG has received travel grants and speaker’s honoraria from Fresenius Medical Care, Neuraxpharm, Servier, and Janssen as well as research funding from Fresenius Medical Care. GS has received honoraria for participating at advisory board meetings from Roche and Biogen regarding new Alzheimer’s disease drugs. KKS has received consultant and speaker’s honoraria from Roche and OrionPharma, reimbursement of travel and accommodation costs at a meeting from Kolpharma, and sponsorships for arranging conferences from Desitin and Eisai AB. IG has received speaker’s honorarium from Lundbeck. MMN has received fees for membership in an advisory board from HMG Systems Engineering GmbH, for membership in the Medical-Scientific Editorial Office of the Deutsches Ärzteblatt, and for serving as a consultant for Everis Belgium in a project of the European Commission (REFORM/SC2020/029). MMN also receives salary payments from Life & Brain GmbH and holds shares in Life & Brain GmbH. All these concerned activities outside the submitted work. CP received honoraria for talks from Lundbeck, Australia Pty Ltd. outside the submitted work. DJS has received consultancy honoraria from Discovery Vitality, Johnson & Johnson, Kanna, L’Oreal, Lundbeck, Orion, Sanofi, Servier, Takeda and Vistagen. JH has received speaker’s honorarium from Medice and Takeda outside the submitted work. KP reports work with Novo Nordisk and Roche clinical trials outside the submitted work. All other authors report no biomedical financial interests or potential conflicts of interest., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs

  • Sønderby, Ida E.
  • Ching, Christopher R. K.
  • Thomopoulos, Sophia I.
  • Meer, Dennis van der
  • Sun, Daqiang
  • Villalón-Reina, Julio E.
  • Agartz, Ingrid
  • Amunts, Katrin
  • Arango, Celso
  • Armstrong, Nicola J.
  • Ayesa-Arriola, Rosa
  • Bakker, Geor
  • Bassett, Anne S.
  • Boomsma, Dorret I.
  • Bülow, Robin
  • Butcher, Nancy J.
  • Calhoun, Vince D.
  • Caspers, Svenja
  • Chow, Eva W C
  • Cichon, Sven
  • Ciufolini, Simone
  • Craig, Michael C.
  • Crespo-Facorro, Benedicto
  • Cunningham, Adam C.
  • Dale, Anders M.
  • Dazzan, Paola
  • de Zubicaray, Greig I.
  • Djurovic, Srdjan
  • Doherty, Joanne L.
  • Donohoe, Gary
  • Draganski, Bogdan
  • Durdle, Courtney A.
  • Ehrlich, Stefan
  • Emanuel, Beverly S.
  • Espeseth, Thomas
  • Fisher, Simon E.
  • Ge, Tian
  • Glahn, David C.
  • Grabe, Hans J.
  • Gur, Raquel E.
  • Gutman, Boris A.
  • Haavik, Jan
  • Håberg, Asta K.
  • Hansen, Laura A.
  • Hashimoto, Ryota
  • Hibar, Derrek P.
  • Holmes, Avram J.
  • Hottenga, Jouke-Jan
  • Hulshoff Pol, Hilleke E
  • Jalbrzikowski, Maria
  • Knowles, Emma E. M.
  • Kushan, Leila
  • Linden, David E J.
  • Liu, Jingyu
  • Lundervold, Astri J.
  • Martin-Brevet, Sandra
  • Martínez, Kenia
  • Mather, Karen A.
  • Mathias, Samuel R.
  • McDonald-McGinn, Donna M.
  • McRae, Allan F.
  • Medland, Sarah E.
  • Moberget, Torgeir
  • Modenato, Claudia
  • Monereo Sánchez, Jennifer
  • Moreau, Clara A.
  • Mühleisen, Thomas W.
  • Paus, Tomas
  • Pausova, Zdenka
  • Prieto, Carlos
  • Ragothaman, Anjanibhargavi
  • Reinbold, Céline S.
  • Reis Marques, Tiago
  • Repetto, Gabriela M.
  • Reymond, Alexandre
  • Roalf, David R.
  • Rodriguez-Herreros, Borja
  • Rucker, James J.
  • Sachdev, Perminder S.
  • Schmitt, James E.
  • Schofield, Peter R.
  • Silva, Ana I.
  • Stefansson, Hreinn
  • Stein, Dan J.
  • Tamnes, Christian K.
  • Tordesillas-Gutiérrez, Diana
  • Ulfarsson, Magnus O.
  • Vajdi, Ariana
  • van 't Ent, Dennis
  • Bree, Marianne B. M. van den
  • Vassos, Evangelos
  • Vázquez-Bourgon, Javier
  • Vila-Rodriguez, Fidel
  • Walters, G Bragi
  • Wen, Wei
  • Westlye, Lars T.
  • Wittfeld, Katharina
  • Zackai, Elaine H.
  • Stefánsson, Kári
  • Jacquemont, Sebastien
  • Thompson, Paul M.
  • Bearden, Carrie E.
  • Andreassen, Ole A.
  • ENIGMA-CNV Working Group
  • ENIGMA 22q11.2 Deletion Syndrome Additional
Data sharing is not applicable to this article as no new data were created or analyzed in this study., ENIGMA-CNV Additional Members: Manon Bernard, Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada. Nicholas B. Blackburn, Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Brownsville, Texas, USA; South Texas Diabetes and Obesity Institute, School of Medicine, University of Texas Rio Grande Valley, Brownsville, Texas, USA. Rune Bøen, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway; Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway. Eco de Geus, Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Amsterdam Public Health (APH) Research Institute, Amsterdam UMC, Amsterdam, The Netherlands. Sonja M. C. de Zwarte, Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Marta Di Forti, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Oleksandr Frei, Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health; Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway and Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway, Vincent Frouin, Université Paris-Saclay, CEA, Neurospin, Gif-sur-Yvette, France. Masaki Fukunaga, Division of Cerebral Integration, National Institute for Physiological Sciences, Okazaki, Japan. Jayne Y. Hehir-Kwa, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Manon H. J. Hillegers, Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Center, Rotterdam, The Netherlands. Per Hoffmann, Institute of Human Genetics, University of Bonn, Bonn, Germany; Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland. Georg Homuth, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany. Neda Jahanshad, Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA. Sanne Koops, Department of Biomedical Sciences of Cells & Systems, Cognitive Neurosciences, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands. Kuldeep Kumar, Sainte Justine Research Center, University of Montreal, Montreal, QC, Canada. Masataka Kikuchi, Graduate School of Medicine, Osaka University, Osaka, Japan. Stephanie Le Hellard, NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway. Costin Leu, Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK; Stanley Center for Psychiatric Research, Broad Institute of Harvard and M.I.T, Cambridge, MA, USA. Robin M Murray, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Terje Nærland, KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway; NevSom, Department of Rare Disorders, Oslo University Hospital, Oslo, Norway. Lars Nyberg, Integrative Medical Biology (IMB) Umeå University, Umeå, Sweden; Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. Roel A. Ophoff, Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, CA, USA; Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. G Bruce Pike, Radiology and Clinical Neurosciences, University of Calgary, Calgary, AB, Canada. Sigrid B. Sando, Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway. Jean Shin, The Hospital for Sick Children, Toronto, ON, Canada; Departments of Physiology and Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada. Elena Shumskaya, Donders Institute for Brain, Cognition, and Behavior, Nijmegen, The Netherlands. Sanjay M. Sisodiya, Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK; Chalfont Centre for Epilepsy, Chalfont-St-Peter, Bucks, UK. Vidar M. Steen, NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway. Alexander Teumer, Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany, Anne Uhlmann, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. Margaret J. Wright, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia, ENIGMA 22q11.2 Deletion Syndrome Additional Members: Kevin M. Antshel, Department of Psychology, Syracuse University, Syracuse, NY, USA. Linda E. Campbell, University of Newcastle, Newcastle, NSW, Australia. Nicolas A. Crossley, Department of Psychiatry, Pontificia Universidad Católica de Chile, Santiago, Chile. T. Blaine Crowley, Division of Human Genetics and 22q and You Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Eileen Daly, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK. Ania M. Fiksinski, Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, ON, Canada; Dalglish Family 22q Clinic for Adults with 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, Toronto, ON, Canada; Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Jennifer K. Forsyth, Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA. Wanda Fremont, Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA. Naomi J. Goodrich-Hunsaker, MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis, Davis, CA, USA; Department of Neurology, University of Utah, Salt Lake City, UT, USA. Maria Gudbrandsen, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK. Rachel K. Jonas, Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Biobehavioral Sciences and Psychology, University of California Los Angeles, Los Angeles, CA, USA. Wendy R. Kates, Department of Psychiatry and Behavioral Sciences, State University of New York at Upstate Medical University, Syracuse, NY, USA. Amy Lin, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, USA. Kathryn L. McCabe, Department of Psychiatry and Behavioral Sciences, State University of New York at Upstate Medical University, Syracuse, NY, USA; Department of Psychology, University of Newcastle, Newcastle, NSW, Australia. Hayley Moss, MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. Declan G. Murphy, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK; Behavioural Genetics Clinic, Adult Autism Service, Behavioural and Developmental Psychiatry Clinical Academic Group, South London and Maudsley NHS Foundation Trust, London, UK. Kieran C. Murphy, Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland. Michael J. Owen, MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. Kosha Ruparel, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Tony. J. Simon, MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis, Davis, CA, USA. Therese van Amelsvoort, Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands. Jacob A. S. Vorstman, Department of Psychiatry, The Hospital for Sick Children, Toronto, ON, Canada., The Enhancing NeuroImaging Genetics through Meta-Analysis copy number variant (ENIGMA-CNV) and 22q11.2 Deletion Syndrome Working Groups (22q-ENIGMA WGs) were created to gain insight into the involvement of genetic factors in human brain development and related cognitive, psychiatric and behavioral manifestations. To that end, the ENIGMA-CNV WG has collated CNV and magnetic resonance imaging (MRI) data from ~49,000 individuals across 38 global research sites, yielding one of the largest studies to date on the effects of CNVs on brain structures in the general population. The 22q-ENIGMA WG includes 12 international research centers that assessed over 533 individuals with a confirmed 22q11.2 deletion syndrome, 40 with 22q11.2 duplications, and 333 typically developing controls, creating the largest-ever 22q11.2 CNV neuroimaging data set. In this review, we outline the ENIGMA infrastructure and procedures for multi-site analysis of CNVs and MRI data. So far, ENIGMA has identified effects of the 22q11.2, 16p11.2 distal, 15q11.2, and 1q21.1 distal CNVs on subcortical and cortical brain structures. Each CNV is associated with differences in cognitive, neurodevelopmental and neuropsychiatric traits, with characteristic patterns of brain structural abnormalities. Evidence of gene-dosage effects on distinct brain regions also emerged, providing further insight into genotype–phenotype relationships. Taken together, these results offer a more comprehensive picture of molecular mechanisms involved in typical and atypical brain development. This “genotype-first” approach also contributes to our understanding of the etiopathogenesis of brain disorders. Finally, we outline future directions to better understand effects of CNVs on brain structure and behavior., The ENIGMA Consortium is supported by the NIH Big Data to Knowledge (BD2K) program under consortium grant number U54 EB020403 (PI: Thompson). OAA is supported by the Research Council of Norway, South East Norway Health Authority, KG Jebsen Stiftelsen, EU H2020. C. A. has been funded by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds; European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241,909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603,196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602,478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative two Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso and Fundación Alicia Koplowitz. R. A-A is funded by a Miguel Servet contract from the Carlos III Health Institute (CP18/00003). G. B. is supported by the Dutch Organization for Health Research and Development ZonMw (grants 91112002 & 91712394). A. S. B. is supported by the Dalglish Family Chair in 22q11.2 Deletion Syndrome, Canadian Institutes of Health Research (CIHR) grants MOP-79518, MOP-89066, MOP-97800 and MOP-111238, and NIMH grant number U01 MH101723–01(3/5). C. E. B. is also supported by the National Institute of Mental Health: RO1 MH085953, R01 MH100900 and 1U01MH119736. N. E. B. is granted the KNAW Academy Professor Award (PAH/6635). V. D. C. is supported by NIH R01 MH094524. S. C. is supported by the European Union's Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 945539 (Human Brain Project SGA3); Helmholtz Initiative and Networking Fund. C. R. K. C. is supported by NIA T32AG058507. E. W. C. C. is supported by the Canadian Institutes of Health Research, Ontario Mental Health Foundation grant MOP-74631 and NIMH grant U01MH101723–01(3/5). S. Ci. has received funding from the European Union's Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 945539 (Human Brain Project SGA3). M. C. C. is supported by the Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. N. A. C. is supported by Agencia Nacional de Investigación y Desarrollo (ANID Chile) PIA ACT192064. GId. Z. is supported by the NHMRC. J. L. D. and D. E. J. L. are supported by the Wellcome Trust. T. B. C. is supported by NICHD grant PO1-HD070454, NIH grant UO1-MH191719, and NIMH grant R01 MH087636-01A1. AMD is supported by U24DA041147. B. D. is supported by the Swiss National Science Foundation (NCCR Synapsy, project grant numbers 32003B_135679, 32003B_159780, 324730_192755 and CRSK-3_190185), the Leenaards Foundation and the Roger De Spoelberch Foundation. SE is supported by the NARSAD-Young Investigator Grant “Epigenetic Regulation of Intermediate Phenotypes in Schizophrenia”. B. E. S. is supported by the NIH (NIMH). D. C. G. is supported by NIH grant numbers MH078143, MH083824, AG058464. W. R. K. is supported by NIH/MH R0106824. R. E. G. is supported by NIH/NIMH grant numbers MH087626, MH119737. DMMcD-McG is supported by National Institutes of Mental Health (NIMH), grant numbers MH119737-02; MH191719; and MH087636-01A1. S. E. M. is supported by NHMRC grants APP1103623; APP1158127; APP1172917. TM is supported by Research Council of Norway - grant number 273345. D. G. M. is supported by the National Institute for Health Research Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and EU-AIMS (European Autism Interventions)/EU AIMS-2-TRIALS, a European Innovative Medicines Initiative Joint Undertaking under grant agreements 115300 and 777394. T. N. was supported by Stiftelsen KG Jebsen under grant number SKGJ-MED-021. R. A. O. is supported by NIMH R01 MH090553. S. Y. S. has been funded by the Canadain Institutes of Health Research. M. J. O. is supported by MRC Centre grant MR/L010305/1 and Wellcome Trust grant 100,202/Z/12/Z; Dr. Owen has received research support from Takeda. Z. P. is supported by CIHR, CFI, HSFC. B. G. P. is supported by CIHR FDN 143290 and CAIP Chair. G. M. R. is supported by Fondecyt-Chile #1171014 and ANID-Chile ACT192064. A. Re. was supported by a grant from the Swiss National Science Foundation (31003A_182632). DRR is supported by R01 MH120174 (PI: Roalf). This report represents independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London (to J. J. R). PSS is supported by NHMRC (Australia) program grant 1093083. J. E. S. is supported by NIH K01-ES026840. S. M. S. is supported by the Epilepsy Society. T. J. S. is supported by NIH grants R01MH107108, R01HD042794, and HDU54079125. I. E. S. is supported by South-Eastern Norway Regional Health Authority (#2020060), European Union's Horizon2020 Research and Innovation Programme (CoMorMent project; grant #847776) and the KG Jebsen Foundation (SKGJ-MED-021). V. M. S. is supported by Research Council of Norway (CoE funding scheme, grant number 223273). D. J. S. is supported by the SA MRC. C. K. T. is supported by Research Council of Norway (#230345, #288083, #223273) and South-Eastern Norway Regional Health Authority (#2019069, #2021070, #500189). D. T.-G. was supported by the Instituto de Salud Carlos III (PI14/00639 and PI14/00918) and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363). Dvd. M. is supported by Research Council of Norway #276082. F. V. R. is supported by the Michael Smith Foundation for Health Research Scholar Award. deCODE genetics has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreements' no. 115008 (NEWMEDS) and no. 115300 (EUAIMS), of which resources are composed of EFPIA in-kind contribution and financial contribution from the European Union's Seventh Framework Programme (EU-FP7/2007–2013). L. T. W. is supported by Research Council of Norway, European Research Council. The IDIVAL neuroimage unit is supported by Instituto de Salud Carlos III PI020499, research funding SCIII-INT13/0014, MICINN research funding SAF2010-20840-C02-02, SAF2013-46292-R. The TOP/NORMENT study are supported by the Research Council of Norway (#223273). The GOBS study data collection was supported in part by the National Institutes of Health (NIH) grants: R01 MH078143, R01 MH078111, and R01 MH083824 with work conducted in part in facilities constructed under the support of NIH grant number C06 RR020547. The Sydney Memory and Ageing Study has been funded by three National Health & Medical Research Council (NHMRC) Program Grants (ID No. ID350833, ID568969, and APP1093083). We thank the participants and their informants for their time and generosity in contributing to this research. We also acknowledge the MAS research team: https://cheba.unsw.edu.au/research-projects/sydney-memory-and-ageing-study. We acknowledge the contribution of the OATS research team (https://cheba.unsw.edu.au/project/older-australian-twins-study) to this study. The OATS study has been funded by a National Health & Medical Research Council (NHMRC) and Australian Research Council (ARC) Strategic Award Grant of the Aging Well, Aging Productively Program (ID No. 401162); NHMRC Project (seed) Grants (ID No. 1024224 and 1025243); NHMRC Project Grants (ID No. 1045325 and 1085606); and NHMRC Program Grants (ID No. 568969 and 1093083). We thank the participants for their time and generosity in contributing to this research. This research was facilitated through access to Twins Research Australia, a national resource supported by a Centre of Research Excellence Grant (ID No. 1079102) from the National Health and Medical Research Council. The NCNG sample collection was supported by grants from the Bergen Research Foundation and the University of Bergen, the Dr Einar Martens Fund, the KG Jebsen Foundation, the Research Council of Norway, to S. L. H., V. M. S., A. J. L., and T. E. The authors thank Dr. Eike Wehling for recruiting participants in Bergen, and Professor Jonn-Terje Geitung and Haraldplass Deaconess Hospital for access to the MRI facility. Additional support by RCN grants 177458/V50 and 231286/F20. The Betula study was supported by a Wallenberg Scholar Grant (KAW). The HUNT Study is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU—Norwegian University of Science and Technology), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology, and the Norwegian National Advisory Unit for functional MRI. Research for the GAP cohort was supported by the Department of Health via the National Institute for Health Research (NIHR) Specialist Biomedical Research Center for Mental Health award to South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry at King's College London, London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. S.J. is supported by Calcul Quebec (http://www.calculquebec.ca), Compute Canada (http://www.computecanada.ca), the Brain Canada Multi investigator research initiative (MIRI), the Institute of Data Valorization (Canada First Research Excellence Fund), CHIR, Canada Research Chairs and the Jeanne et Jean Louis Levesque Foundation. The NTR cohort was supported by the Netherlands Organization for Scientific Research (NWO), MW904-61-193 (de Geus & Boomsma), MaGWnr: 400-07-080 (van 't Ent), MagW 480-04-004 (Boomsma), NWO/SPI 56-464-14,192 (Boomsma), the European Research Council, ERC-230374 (Boomsma), and Amsterdam Neuroscience. Funding for genotyping was obtained from the National Institutes of Health (NIMH U24 MH068457-06; Grand Opportunity grants 1RC2 MH089951, and 1RC2 MH089995); the Avera Institute for Human Genetics, Sioux Falls, South Dakota (USA). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. The Brainscale study was supported by the Netherlands Organization for Scientific Research MagW 480-04-004 (Boomsma), 51.02.060 (Hilleke Hulshoff Pol), 668.772 (Boomsma & Hulshoff Pol); NWO/SPI 56-464-14192 (Boomsma), the European Research Council (ERC230374) (Boomsma), High Potential Grant Utrecht University (Hulshoff Pol), NWO Brain and Cognition 433-09-220 (Hulshoff Pol). SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide SNP typing in SHIP and MRI scans in SHIP and SHIP-TREND have been supported by a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. The ENIGMA-22q11.2 Deletion Syndrome Working Group wishes to acknowledge our dear colleague Dr. Clodagh Murphy, who sadly passed away in April 2020. Open access funding enabled and organized by Projekt DEAL., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Penetrance of neurodevelopmental copy number variants is associated with variations in cortical morphology

  • Silva, Ana I.
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
  • Linden, David E. J.
  • ENIGMA-CNV Working Group
ENIGMA-CNV Working Group: et al, [Background] Copy number variants (CNVs) may increase the risk for neurodevelopmental conditions. The neurobiological mechanisms that link these high-risk genetic variants to clinical phenotypes are largely unknown. An important question is whether brain abnormalities in individuals who carry CNVs are associated with their degree of penetrance., [Methods] We investigated whether increased CNV penetrance for schizophrenia and other developmental disorders was associated with variations in cortical and subcortical morphology. We pooled T1-weighted brain magnetic resonance imaging and genetic data from 22 cohorts from the ENIGMA (Enhancing Neuro Imaging Genetics through Meta Analysis)-CNV consortium. In the main analyses, we included 9268 individuals (aged 7–90 years, 54% female), from which we identified 398 carriers of 36 neurodevelopmental CNVs at 20 distinct loci. A secondary analysis was performed including additional neuroimaging data from the ENIGMA-22q consortium, including 274 carriers of the 22q11.2 deletion and 291 noncarriers. CNV penetrance was estimated through penetrance scores that were previously generated from large cohorts of patients and controls. These scores represent the probability risk of developing either schizophrenia or other developmental disorders (including developmental delay, autism spectrum disorder, and congenital malformations)., [Results] For both schizophrenia and developmental disorders, increased penetrance scores were associated with lower surface area in the cerebral cortex and lower intracranial volume. For both conditions, associations between CNV-penetrance scores and cortical surface area were strongest in regions of the occipital lobes, specifically in the cuneus and lingual gyrus., [Conclusions] Our findings link global and regional cortical morphometric features with CNV penetrance, providing new insights into neurobiological mechanisms of genetic risk for schizophrenia and other developmental disorders., 16p11.2 Consortium: This work was supported by Compute Canada, the Brain Canada Multi investigator research initiative, Canada First Research Excellence Fund, the Institute of Data Valorization, and Healthy Brain Healthy Lives. SJ is a recipient of a Canada Research Chair in neurodevelopmental disorders and a chair from the Jeanne et Jean Louis Levesque Foundation. This work was supported by the Canadian Institutes of Health Research (CIHR) (Grant Nos. 400528 and 438531) and Innovative Medicines Initiative 2 Joint Undertaking (Grant No. 777394) for AIMS-2-TRIALS. This Joint Undertaking receives support from the EU’s Horizon 2020 program, EFPIA, Autism Speaks, Autistica, and SFARI. KK was supported by The Institute of Data Valorization Postdoctoral Fellowship program, through the Canada First Research Excellence Fund. COBRE (Centers of Biomedical Research Excellence): This research is funded by National Science Foundation (Grant No. 2112455) and National Institutes of Health (NIH) (Grant No. R01MH118695). Dublin: This research is funded by European Research Council (Grant No. 677467). ECHO-DEFINE: The ECHO (Experiences of Children with Copy Number Variants) study acknowledges funding from the Wellcome Trust (Institutional Strategic Support Fund) (to MBMvdB) and Clinical Research Training Fellowship (Grant No. 102003/Z/13/Z [to JLD]), the Waterloo Foundation (Grant No. WF 918- 1234 [to MBMvdB]), the Baily Thomas Charitable Fund (Grant No. 2315/1 [to MBMvdB]), National Institute of Mental Health (NIMH) (Grant No. 5UO1MH101724) and NIMH (Grant No. U01MH119738 [to MBMvdB]), the IMAGINE-ID and IMAGINE-2 studies (funded by Medical Research Council [MRC]) (Grant Nos. MR/N022572/1 and MR/T033045/1 [to MBMvdB]) and an MRC Centre Grant (Grant No. MR/P005748/1 [to MJO]). The DEFINE (Defining Endophenotypes From Integrative Neuroscience) study was supported by a Wellcome Trust Strategic Award (Grant No. 100202/Z/12/Z [to MJO]). ENIGMA: The ENIGMA Working Group acknowledges the NIH Big Data to Knowledge award for foundational support and consortium development (Grant No. U54 EB020403 [to PMT]). For a complete list of ENIGMA-related grant support, please see here: http://enigma.ini.usc.edu/about-2/funding/. PMT and SIT are also supported in part by ENIGMA NIH (Grant Nos. R01MH116147, R01NS107513, R01AG058854, and R01MH129742). IES is supported by the Research Council of Norway (Grant No. 223273), South-Eastern Norway Regional Health Authority (Grant No. 2020060), European Union’s Horizon2020 Research and Innovation Programme (CoMorMent project) (Grant No. 847776), and Kristian Gerhard Jebsen Stiftelsen (Grant No. SKGJ-MED-021). South-Eastern Norway Regional Health Authority (Grant No. 2020060) also supports RBo. This work was partially performed on Services for Sensitive Data (TSD), University of Oslo, Norway, with resources provided by UNINETT Sigma2, the National Infrastructure for High Performance Computing and Data Storage in Norway. OAA is supported by Research Council of Norway (Grant No. 223273) and KG Jebsen Stiftelsen (Grant No. SKGJ-MED-021). NJ is supported by NIH (Grant No. R01MH117601). DvdM is supported by Research Council of Norway (Grant No. 276082). ENIGMA-22q: This research is supported by NIMH (Grant Nos. R01MH085953, R21MH116473, and 9U01MH119736-02). ASB is supported by the Dalglish Family Chair in 22q11.2 Deletion Syndrome, CIHR (Grant Nos. MOP-79518, MOP-89066, MOP-97800, and MOP-111238) and NIMH (Grant No. U01MH101723–01[3/5]). EWCC acknowledges support from the CIHR (Grant No. MOP-74631) and Ontario Mental Health Foundation for the current work. DRR is supported by NIMH (Grant No. R01 119185). JES is supported by the Stanford Maternal and Child Health Research Institute Uytengsu-Hamilton 22q11 Neuropsychiatry Research Awards Program (Grant No. UH22QEXTFY21). DMM-M acknowledges support from NIMH (Grant No. U01MH119737). JASV acknowledges funding support from NIMH (Grant Nos. 1U01MH119741-01 and 3U01MH119741-02S1). TvA acknowledges financial support from NIMH (Grant No. 5U01 MH119740). GAP: PD’s research is supported by the MRC and the Wellcome Trust. Funding was received from the Psychiatry Research Trust, the Wellcome Trust, the MRC, and the National Institute for Health Research (NIHR) Biomedical Research Centre at the South London and Maudsley NHS Trust. The funding sources were not involved in carrying out or interpreting the study. GOBS: The GOBS (Genetics of Brain Structure and Function study) data collection was supported in part by NIH (Grant Nos. R01MH078143 and R01MH083824). Haavik: This research is supported by Stiftelsen KG Jebsen (Grant No. SKGJ MED-02), the Research Council of Norway, and Helse Vest RHF. HUBIN (Human Brain Informatics): This research is supported by Swedish Research Council (Grant Nos. K2007-62X-15077-04-1, K2008-62P-20597-01-3, K2010-62X-15078-07-2, K2012-61X-15078-09-3, K2015-62X-15077-12-3, and 2017-00949), the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, and the Research Council of Norway (Grant No. 274 359). HUNT: The HUNT (Trøndelag Health Study) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology), North Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology and the Norwegian National Advisory Unit for functional MRI. IMAGEN: The European Union–funded FP6 Integrated Project IMAGEN (Reinforcement-related behavior in normal brain function and psychopathology) (Grant No. LSHM-CT- 2007-037286), the Horizon 2020 funded ERC Advanced Grant STRATIFY (Brain network based stratification of reinforcement-related disorders) (Grant No. 695313), Human Brain Project (Grant Nos. HBP SGA 2, 785907, and HBP SGA 3, 945539), the MRC Grant c-VEDA (Consortium on Vulnerability to Externalizing Disorders and Addictions) (Grant No. MR/N000390/1), NIH (Grant No. R01DA049238), A decentralized macro and micro gene-by-environment interaction analysis of substance use behavior and its brain biomarkers), the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, the Bundesministerium für Bildung und Forschung (Grant Nos. 01GS08152; 01EV0711; Forschungsnetz AERIAL 01EE1406A, 01EE1406B; Forschungsnetz IMAC- Mind 01GL1745B), the Deutsche Forschungsgemeinschaft (DFG Grant Nos. SM 80/7-2, SFB 940, TRR 265, NE 1383/14-1), ImagenPathways “Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways” is a collaborative project supported by the European Research Area Network on Illicit Drugs, the Medical Research Foundation and MRC (Grant Nos. MR/R00465X/1 and MR/S020306/1), the NIH-funded ENIGMA (Grant Nos. 5U54EB020403-05 and 1R56AG058854-01), National Natural Science Foundation of China (NSFC) (Grant No. 82 150 710 554), and European Union–funded project environMENTAL (Grant No. 101057429). Additional support was provided by grants from the ANR (Grant Nos. ANR-12-SAMA-0004, AAPG2019—GeBra), the Eranet Neuron (Grant Nos. AF12-NEUR0008-01—WM2NA; and ANR-18-NEUR00002-01—ADORe), the Fondation de France (Grant No. 00081242), the Fondation pour la Recherche Médicale (Grant No. DPA20140629802), the Mission Interministérielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives, the Assistance Publique-Hôpitaux de Paris and Institut National de la Santé et de la Recherche Médicale (INSERM) (interface grant), Paris Sud University IDEX 2012, the Fondation de l’Avenir (Grant No. AP-RM-17-013), the Fédération pour la Recherche sur le Cerveau; the NIH, Science Foundation Ireland (Grant No. 16/ERCD/3797), the Science Foundation Ireland (Grant No. 16/ERCD/3797), the NIH (Axon, Testosterone and Mental Health during Adolescence) (Grant No. R01MH085772-01A1), and the NIH Consortium (Grant No. U54 EB020403), supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence. The INSERM, the Strasbourg University, and SATT CONECTUS, provided sponsorship (principal investigator: J-LM). TP is supported by NIH (Grant No. R01MH085772). Gilles Berstchy is acknowledged for his support. Stephane Lehericy and the radiographer staff at Centre de NeuroImagerie de Recherche de l'’Institut du Cerveau (http://www.cenir.org/mri.html?lang=en) are acknowledged for their support in acquisition of MRI datasets. MCIC (Mind Clinical Imaging Consortium): This research is funded by NIH study P20GM103472. METH-CT: DJS is supported by the South African Medical Research Council (SAMRC). FS is supported by a PDRF (Presidential Doctoral Research Fellowship) from the Brain Behavior Unit, Department of Psychiatry and Mental Health, University of Cape Town. SD is supported by the Biomedical Research and Innovation Platform and SAMRC. NCNG: NCNG (Norwegian Cognitive NeuroGenetics sample) was supported by the Bergen Research Foundation, the University of Bergen, the Research Council of Norway (FUGE) (Enhance Research in Functional Genomics) (Grant Nos. 151904 and 183327), Psykisk Helse (Grant No. 175345), RCN (Grant Nos. 154313/V50 [to Ivar Reinvang] and 177458/V50 [to TE]), Helse SørØst RHF (Grant No. 2012086 [to TE]), and the Dr. Einar Martens Fund. NTR: The NTR cohort was supported by the Netherlands Organization for Scientific Research (NWO) and The Netherlands Organization for Health Research and Development (ZonMW) (Grant Nos. 904-61-090, 985-10-002, 912-10-020, 904-61-193, 480-04-004, 463-06-001, 451-04-034, 400-05-717, Addiction-31160008, 016-115-035, 481-08-011, 400-07-080, 056-32-010, Middelgroot-911-09-032, OCW_NWO Gravity program –024.001.003, NWO-Groot 480-15-001/674), Center for Medical Systems Biology (CMSB, NWO Genomics), NBIC/BioAssist/RK(2008.024), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) (Grant Nos. NL, 184.021.007 and 184.033.111), X-Omics 184-034-019; Spinozapremie (Grant No. NWO- 56-464-14192), KNAW Academy Professor Award (PAH/6635) and University Research Fellow grant (to DIB); Amsterdam Public Health Research Institute (former EMGO+), Neuroscience Amsterdam research institute (former NCA); the European Community’s Fifth and Seventh Framework Program (Grant Nos. FP5- LIFE QUALITY-CT-2002-2006, FP7-HEALTH-F4-2007-2013, Grant No. 01254: GenomEUtwin, Grant No. 01413: ENGAGE and Grant No. 602768:ACTION); the European Research Council (Grant Nos. ERC Starting 284 167, ERC Consolidator 771057, ERC Advanced 230374), Rutgers University Cell and DNA Repository (NIMH) (Grant No. U24 MH068457-06), NIH (Grant Nos. R01D0042157-01A1, R01MH58799-03, MH081802, DA018673, R01DK092127-04), Grand Opportunity (Grant Nos. 1RC2 MH089951 and 1RC2 MH089995); and the Avera Institute for Human Genetics, Sioux Falls, South Dakota. Part of the genotyping and analyses were funded by the Genetic Association Information Network of the Foundation for the NIH. Computing was supported by NWO (Grant No. 2018/EW/00408559), BiG Grid, the Dutch e-Science Grid, and SURFSARA. OATS1/OATS2 and Sydney MAS: The OATS (Older Australian Twins Study) has been funded by a National Health & Medical Research Council (NHMRC) and Australian Research Council (ARC) Strategic Award Grant of the Ageing Well, Ageing Productively Program (Grant No. 401162); NHMRC Project (seed) Grants (Grant Nos. 1024224 and 1 025 243); NHMRC Project Grants (Grant Nos. 1045325 and 1085606); and NHMRC Program Grants (Grant Nos. 568969 and 1093083). This research was facilitated through access to Twins Research Australia, which is a national resource supported by a Centre of Research Excellence Grant (Grant No. 1079102) from the NHMRC. The Sydney Memory and Ageing Study has been funded by 3 NHMRC Program Grants (Grant Nos. ID350833, ID568969, and APP1093083). Core funding was received from the NSW Government Department of Health and the Australian government Department of Health and Aged Care; NHMRC Leadership Fellowship (Grant No. GNT2009771); NHMRC (Grant No. GNT1045325). DNA samples were extracted by Genetic Repositories Australia, an Enabling Facility, which was supported by an NHMRC Grant (Grant No. 401184). MRI scans were processed with the support of NHMRC Project Grants (Grant Nos. 510175 and 1025243) and an ARC Discovery Project Grant (Grant No. DP0774213) and John Holden Family Foundation. PAFIP: This study was supported by grants from Carlos III Health Institute (Grant Nos. IPI17/00402, PI17/01056, PI14/00639, and PI14/00918) cofunded by the European Union through FEDER funds and Fundación Instituto de Investigación Marqués de Valdecilla (Grant Nos. NCT0235832 and NCT02534363). No pharmaceutical company has financially supported the study. JV-B acknowledges IDIVAL Grants (Grant Nos. INT/A21/10 and INT/A20/04). QTIM: The QTIM study was supported by grants from the U.S. National Institute of Child Health and Human Development (Grant No. R01HD050735) and the Australian NHMRC (Grant Nos. 486682, 1009064). Genotyping was supported by NHMRC (Grant No. 389875). AFM is funded by an ARC Future Fellowship (Grant No. FT200100837). SEM is supported by NHMRC Investigator Grant (Grant No. APP1172917). SHIP-2/SHIP-TREND: SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (Grant Nos. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network “Greifswald Approach to Individualized Medicine (GANI_MED)” funded by the Federal Ministry of Education and Research (Grant No. 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (Grant No. 03ZIK012) and a joint grant from Siemens Healthineers and the Federal State of Mecklenburg-West Pomerania. The University of Greifswald is a member of the Caché Campus program of the InterSystems GmbH. This study has received funding from the following institutions: Federal Ministry of Education and Research, the Ministry of Cultural Affairs, as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania. MRI examinations were supported by Siemens Healthineers, Siemens Healthcare GmbH. AT has been funded by DFG (Grant No. 542489987). The SHIP authors thank Holger Prokisch and Thomas Meitinger (Helmholtz Zentrum München) for the genotyping of the SHIP-TREND cohort. Stroke (TOP_T3): The European Research Council under the European Union’s Horizon 2020 research and Innovation program (Grant No. ERC 802998). The Research Council of Norway (Grant Nos. 298646 and 300767), and the South-Eastern Norway Regional Health Authority (Grant Nos. 2013054, 2015044, 2015073, 2018076, 2019101, and 2020060)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Transdiagnostic alterations in white matter microstructure associated with suicidal thoughts and behaviours in the ENIGMA Suicidal Thoughts and Behaviours consortium

  • Velzen, Laura S. van
  • Colic, Lejla
  • Ceja, Zuriel
  • Dauvermann, Maria R.
  • Villa, Luca M.
  • Savage, Hannah S.
  • Toenders, Yara J.
  • Dehestani, Niousha
  • Zhu, Alyssa H.
  • Campos, Adrian I.
  • Salminen, Lauren E.
  • Valabregue, Romain
  • Valencia-Echeverry, Johanna
  • Wagner, Gerd
  • Waiter, Gordon
  • Walter, Martin
  • Whalley, Heather C.
  • Wu, Mon-Ju
  • Yang, Tony T.
  • Zarate, Carlos A.
  • Zugman, Andre
  • Alda, Martin
  • Zunta-Soares, Giovana B.
  • Heeringen, Kees van
  • Rooij, Sanne J. H. van
  • Wee, Nic van der
  • Werff, Steven van der
  • Paul M. Thompson,
  • Blumberg, Hilary P.
  • Harmelen, Anne-Laura van
  • Rentería, Miguel E.
  • Jahanshad, Neda
  • Agartz, Ingrid
  • ENIGMA Suicidal Thoughts and Behaviours Consortium
  • Schmaal, Lianne
  • Alexander, Nina
  • Ayesa Arriola, Rosa
  • Ballard, Elizabeth D.
  • Banaj, Nerisa
  • Barkhau, Carlotta
  • Başgöze, Zeynep
  • Bauer, Jochen
  • Benedetti, Francesco
  • Berger, Klaus
  • Besteher, Bianca
  • Brosch, Katharina
  • Canal-Rivero, Manuel
  • Cervenka, Simon
  • Colle, Romain
  • Connolly, Colm G.
  • Corruble, Emmanuelle
  • Courtet, Philippe
  • Couvy-Duchesne, Baptiste
  • Crespo-Facorro, Benedicto
  • Cullen, Kathryn R.
  • Udo Dannlowski,
  • Deverdun, Jeremy
  • Diaz-Zuluaga, Ana M.
  • Dietze, Lorielle M. F.
  • Evans, Jennifer W.
  • Fani, Negar
  • Flinkenflügel, Kira
  • Friedman, Naomi P.
  • Gotlib, Ian H.
  • Groenewold, Nynke A.
  • Grotegerd, Dominik
  • Hajek, Tomas
  • Hatoum, Alexander S.
  • Hermesdorf, Marco
  • Hickie, Ian B.
  • Hirano, Yoshiyuki
  • Ho, Tiffany C.
  • Ikemizu, Yuki
  • Iorfino, Frank
  • Ipser, Jonathan C.
  • Yuko, Isobe
  • Jackowski, Andrea P.
  • Jollant, Fabrice
  • Kircher, Tilo
  • Klug, Melissa
  • Koopowitz, Sheri-Michelle
  • Kraus, Anna
  • Krug, Axel
  • Le Bars, Emmanuelle
  • Leehr, Elisabeth J.
  • Li, Meng
  • Lippard, Elizabeth T. C.
  • López-Jaramillo, Carlos
  • Maximov, Ivan I.
  • McIntosh, Andrew M.
  • McLaughlin, Katie A.
  • McWhinney, Sean R.
  • Meinert, Susanne
  • Melloni, Elisa
  • Mitchell, Philip B.
  • Mwangi, Benson
  • Nenadić, Igor
  • Nerland, Stener
  • Olie, Emilie
  • Ortiz-Garcia de la Foz, Victor
  • Pan, Pedro M.
  • Pereira, Fabricio
  • Piras, Fabrizio
  • Piras, Federica
  • Poletti, Sara
  • Reineberg, Andrew E.
  • Roberts, Gloria
  • Romero-García, Rafael
  • Sacchet, Matthew D.
  • Salum, Giovanni A.
  • Sandu, Anca-Larisa
  • Sellgren, Carl M.
  • Shimizu, Eiji
  • Smolker, Harry R.
  • Soares, Jair C.
  • Steele, J. Douglas
  • Frederike Stein,
  • Stein, Dan J.
  • Straube, Benjamin
  • Teutenberg, Lea
  • Thomas-Odenthal, Florian
  • Usemann, Paula
[Data availability] The datasets analysed in the current study are not publicly available due to privacy restrictions., Previous studies have suggested that alterations in white matter (WM) microstructure are implicated in suicidal thoughts and behaviours (STBs). However, findings of diffusion tensor imaging (DTI) studies have been inconsistent. In this large-scale mega-analysis conducted by the ENIGMA Suicidal Thoughts and Behaviours (ENIGMA-STB) consortium, we examined WM alterations associated with STBs. Data processing was standardised across sites, and resulting WM microstructure measures (fractional anisotropy (FA), axial diffusivity (AD), mean diffusivity and radial diffusivity) for 24 WM tracts and one global measure were pooled across 40 cohorts. We compared these measures among individuals with a psychiatric diagnosis and lifetime history of suicide attempt (n = 652; mean age = 35.4 ± 14.7; female = 71.8%), individuals with a psychiatric diagnosis but no STB (i.e., clinical controls; n = 1871; mean age = 34 ± 14.8; female = 59.8%), and individuals with no psychiatric diagnosis and no STB (i.e., healthy controls; n = 642; mean age = 29.6 ± 13.1; female = 62.9%). We also compared these measures among individuals with recent suicidal ideation (n = 714; mean age = 36.3 ± 15.3; female = 66.1%), clinical controls (n = 1184; mean age = 36.8 ± 15.6; female = 63.1%), and healthy controls (n = 1240; mean age = 31.6 ± 15.5; female = 61.0%). We found subtle but statistically significant effects, such as lower FA associated with a history of suicide attempt, over and above the effect of psychiatric diagnoses. These effects were strongest in the corona radiata, thalamic radiation, fornix/stria terminalis, corpus callosum and superior longitudinal fasciculus. Recent suicidal ideation was associated with higher AD in the cingulum. Effect sizes were small (partial eta-squared < 0.015). This large-scale coordinated mega-analysis revealed subtle regional and global alterations in WM microstructure in individuals with a history of suicide attempt and recent suicidal ideation. Longitudinal studies are needed to confirm whether these alterations are a risk factor for suicidal behaviour or ideation., This work was supported by the MQ Brighter Futures Award MQBFC/2 (LS, LC, MD, LvV, ALvH, HB) and the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH117601 (LS, LvV, NJ). ALvH was funded by a MQ Brighter Futures Award MQBFC/2, a Royal Society Dorothy Hodgkin Fellowship (DH15017), an MRC MRF emerging leaders award, the Leiden University Social Resilience and Security fund, and an NWO VIDI award. HPB was supported by the MQ Brighter Futures Award MQBFC/2, the National Center for Advancing Translational Science (Grant Number: UL1TR000142), the National Institute of Mental Health (Grant Numbers: RC1MH088366, R01MH69747), Brain and Behavior Research Foundation, International Bipolar Disorders Foundation, American Foundation for Suicide Prevention SRG-1-10-119, and the John and Hope Furth Endowment. EDB is supported by the National Institute of Mental Health Intramural Research Program (ZIA MH002857). NB is supported by the Italian Ministry of Health, grant Ricerca Corrente RC 23. The University of Minnesota adolescent MDD study is supported by the National Institute of Mental Health (K23MH090421), the National Alliance for Research on Schizophrenia and Depression, the University of Minnesota Graduate School, the Minnesota Medical Foundation, and the Biotechnology Research Center (P41 RR008079 to the Center for Magnetic Resonance Research), University of Minnesota, and the Deborah E. Powell Center for Women’s Health Seed Grant, University of Minnesota. FB is supported by the Italian Ministry of Health, grant PNRR-MAD-2022-12375859. BiDirect was funded by grants from the German Federal Ministry of Education and Research (BMBF; Grants FKZ-01ER0816 and FKZ-01ER1506) to KB. BB and LC are supported by the Interdisciplinary Center of Clinical Research of the Medical Faculty Jena. M.C.-R. acknowledges funding support from the Consejería de Salud y Familias (Junta de Andalucía) 2020 grant, which covers his salary (RH-0081-2020). Funding for the DEPARRESTCLIN cohort was provided by a national grant (ANR SAMENTA 2012) of the Agence Nationale de la Recherche (ANR). BCD is funded by a NHMRC CJ Martin fellowship (1161356). BCF acknowledges this work was supported by the Instituto de Salud Carlos III (PI14/00639 and PI14/00918) and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363). UD acknowledges this work was funded by the German Research Foundation (DFG), Udo Dannlowski (co-speaker FOR2107, DA 1151/5-1, DA 1151/5-2, grant DA1151/9-1, DA1151/10-1 and DA1151/11-1) and the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Münster (grant Dan3/022/22 to UD). MuensterNeuroimagingCohort: This work was funded by the German Research Foundation (SFB-TRR58, Project C09 to UD). JWE is supported by the National Institute of Mental Health Intramural Research Program (ZIA MH002857). NPF acknowledges the LTS Colorado data acquisition was supported by grants from the National Institutes of Health (NIH) in the United States (AG046938 and MH063207). NPF was supported by NIH grants AG046938, MH117131, MH124846, DA042742, DA046413, DA046064, and DA051018. IHG is supported by the National Institute of Mental Health Grant R37MH101495. TH acknowledges this study was supported by funding from the Canadian Institutes of Health Research (103703, 106469 and 142255, 180449, 186254), Nova Scotia Health Research Foundation, Dalhousie Clinical Research Scholarship to T. Hajek, Brain & Behavior Research Foundation (formerly NARSAD); 2007 Young Investigator and 2015 Independent Investigator Awards to T. Hajek. This work was also supported by the AMED Brain/MINDS Beyond Program (JP18dm0307002) and JSPS KAKENHI (JP19K03309 and JP22H01090). TCH is supported in part by the National Institutes of Health (K01MH117442, R21MH130817, R01MH127176). YI was supported by JSPS KAKENHI (JP23K07004). FI was supported by an NHMRC EL1 Investigator Grant (GNT2018157) and the Bill and Patricia Richie Foundation Fellowship. YI was supported by JSPS KAKENHI (JP23K02956). FJ acknowledges this study was supported by an operating grant from the Canadian Institutes for Health Research (CIHR #119288). TK acknowledges this work was funded by the German Research Foundation (DFG grants FOR2107 KI588/14-1, and KI588/14-2, and KI588/20-1, KI588/22-1 to Tilo Kircher, Marburg, Germany). Biosamples and corresponding data were sampled, processed and stored in the Marburg Biobank CBBMR. This work was funded by the German Research Foundation (DFG grants KR 3822/5-1, KR 3822/7-2 to Axel Krug). ETCL s funded in part by the American Foundation for Suicide Prevention SRG-0-112-20. CLJ is supported by PRISMA U.T. AMM is supported by the Wellcome Trust Grants (220857/Z/20/Z, 226770/Z/22/Z, 104036/Z/14/Z, 216767/Z/19/Z), and the European Union Horizon 2020 Grant (Grant Agreement 847776). KAM acknowledges this study was funded by the National Institute of Mental Health (R01-MH103291). PBM acknowledges this study was funded by the Australian National Medical and Health Research Council (Program Grant 1037196 (PBM and MB); Investigator Grant 1177991 (PBM)), the Lansdowne Foundation, Good Talk, and the Keith Pettigrew Family Bequest (PBM). IN work is funded by the Deutsche Forschungsgemeinschaft (DFG) grants NE2254/1-2, NE2254/2-1, NE2254/3-1, NE2254/4-1. PMP acknowledges BHRCS was supported with grants from the National Institute of Development Psychiatric for Children and Adolescent (INPD) and the Grant Fapesp 2014/50917-0 - 2021/05332-8 CNPq 465550/2014-2. FP acknowledges support for the team in Nimes, CINES grants access to HPC facilities (A0100311413). FaP is supported by the Italian Ministry of Health, grant RF-2019-12370182. FeP is supported by the Italian Ministry of Health, grant Ricerca Corrente RC 23. SP is supported by the Italian Ministry of Health, grant PNRR-MAD-2022-12375716, RF-2018-12367249. GR acknowledges this study was funded by the Australian National Medical and Health Research Council (Program Grant 1037196 (PBM and MB); Investigator Grant 1177991 (PBM)), the Lansdowne Foundation, Good Talk, and the Keith Pettigrew Family Bequest (PBM). RRG was supported by EMERGIA Junta de Andalucía program (EMERGIA20_00139), the VII Plan Propio of the University of Seville, the Plan de Consolidación (CNS2023-143647) and the Proyectos de Generación de Conocimiento (PID2021-122853OA-I00) from the Spanish Ministry of Science and Innovation. MDS is supported by the National Institute of Mental Health (Project Number R01MH125850); Brain and Behavior Research Foundation (Grant Number 28972). HRS was supported by a grant from the National Institutes of Health in the United States (DA051018). JCS acknowledges this work was partially supported by NIMH (1R01MH085667-01A1), John S. Dunn Foundation (Houston, Texas), and Pat Rutherford Chair in Psychiatry (UTHealth Houston). GS is supported by the Italian Ministry of Health, grant Ricerca Corrente RC 23. JDS is supported by the grants MRC (MR/S010351/1, MR/W002388/1, MR/W002566/1) and EPSRC (EP/Y017544/1). The DCHS cohort is funded by the Bill & Melinda Gates Foundation [INV-006732]. DJS is funded by the South African Medical Research Council. BS acknowledges this work was funded by the German Research Foundation (DFG grant as part of FOR2107: STR1146/18-1 to Benjamin Straube, Marburg, Germany). MW is supported by German Center for Mental Health (DZPG); FKZ: 01EE2103; and NeuroMarKet: Neuroimaging and Blood Markers as Indicators of Ketamine Efficacy in Treatment Resistant Depression; BMBF-EU-EraNet-Neuron, FKZ: 01EW2010A. HCW acknowledges this work is supported by the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6], Scottish Funding Council [HR03006], Wellcome Trust [216767/Z/19/Z] & Wellcome Trust (Wellcome Trust Strategic Award “STratifying Resilience and Depression Longitudinally” (STRADL) Reference 104036/Z/14/Z). CAZ is supported by the National Institute of Mental Health Intramural Research Program (ZIA MH002857). TTY is supported by the National Center for Complementary and Integrative Health (NCCIH) R21AT009173, R61AT009864, and R33AT009864 to TTY; by the National Center for Advancing Translational Sciences (CTSI), National Institutes of Health, through UCSF-CTSI UL1TR001872 to TTY; by the American Foundation for Suicide Prevention (AFSP) SRG-1-141-18 to TTY; by UCSF Weill Institute for Neurosciences to TTY; by UCSF Research Evaluation and Allocation Committee (REAC) and J. Jacobson Fund to TTY; by the National Institute of Mental Health (NIMH) R01MH085734 and the Brain and Behavior Research Foundation (formerly NARSAD) to TTY. PMT is supported by NIH grants R01AG058854, R01MH116147 and R01MH129742. NJ is supported by R01MH134004. MER receives Fellowship support from the Rebecca L Cooper Medical Research Foundation (F20231230)., Peer reviewed